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OXYGENATION AND ACTIVATION OF THE VASTUS LATERALIS DURING 
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MUSCLE ACTIONS IN OLDER WOMEN WITH AND WITHOUT 
SARCOPENIA 
Brianna McKay, M.S. 
University of Nebraska, 2019 
Advisor: Joel Cramer 
The purpose of the present study was to compare muscle strength, size, activation, 
and oxygenation between older women with and without sarcopenia during dynamic 
fatiguing leg extension bouts with high (5-repetition maximum[5-RM]) and low (30% of 
estimated 1-RM[30%1-RM]) loads. Eleven women (n = 6 non-sarcopenic [mean ± SE; 
age = 75.8 ± 2.6y] and n = 5 sarcopenic [age = 74.5 ± 3.1y]) were screened for eligibility 
and sarcopenic status. Descriptive assessments including demographics (age, height, and 
weight), body composition by dual-energy x-ray absorptiometry (fat mass[FM], fat-free 
mass[FFM] and percent body fat[BF%]), muscle size by ultrasonography (leg extensor 
muscle cross-sectional area[mCSA], vastus lateralis [VL] thickness, subcutaneous fat 
thickness, and echo intensity[EI]), muscle strength (leg extensor[5-RM], handgrip[HG]), 
muscular endurance (30%1-RM to exhaustion), and functionality (gait speed) were 
measured. During the 5-RM and 30%1-RM tasks, muscle activation was measured by 
surface electromyography (EMG), while muscle oxygenation was measured by near-
infrared spectroscopy (NIRS). FM, BF%, subcutaneous fat, and EI indicated the presence 
of sarcopenic obesity (p ≤ 0.05). Relative skeletal mass index and HG were lower (p ≤ 
0.05) in the sarcopenic group, but no other descriptive measures were different between 
  
groups (p > 0.05). Despite no differences (p > 0.05) in leg extensor muscle size or 
strength between sarcopenic and non-sarcopenic older women, the sarcopenic women 
exhibited 13 – 21% lower (p ≤ 0.05) muscle oxygenation across all repetitions of the 
high- and low-load tasks. EMG amplitude (EMGRMS) increased, while EMG mean power 
frequency (EMGMPF) decreased (p ≤ 0.05) across repetitions during both tasks, but there 
were no differences between groups. These findings suggest the presence of a clinical 
sarcopenic classification may not uniformly impact the size or strength of all muscles. If 
greater variability is expected among muscle activation strategies of older adults, using 
EMG to distinguish between sarcopenic and non-sarcopenic women without differences 
in leg extensor muscle size, strength, or endurance may be difficult. However, lower 
muscle oxygenation, which may reflect skeletal muscle blood flow, in clinically 
sarcopenic older women may be important to consider when recommending exercise or 
nutrition interventions for either oxygen or dietary nutrient delivery.  
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CHAPTER 1 
INTRODUCTION 
In 2015, the United Nations Department of Economic and Social Affairs 
published a report on World Population Aging where they projected the population of 
adults older than 60 years to nearly double from 66.5 million in 2015 to over 108 million 
by 2050 in the United States alone (73). With increasing life expectancy and a 
dramatically increasing population of older persons, there is a growing interest to 
emphasize the prevention and postponing of age-related disability, specifically through 
nutrition and exercise-related interventions (73). The progressive loss of muscle mass 
with age and the accompanied decreases in strength and function, collectively known as 
sarcopenia, is of particular interest due to the relationship of this condition with increased 
risk of adverse outcomes in older adults (15). Adverse outcomes associated with 
sarcopenia include, but are not limited to, increased risk of falls, fractures, disability, 
institutionalization, and all-cause mortality (10,26,27,37). Furthermore, sarcopenia may 
be prevalent in more than 20% of healthy, community-dwelling adults ages 65 years and 
older and the prevalence increases to as much as 30% in females and 50% in males over 
80 years old (36). More research is needed to understand the mechanisms of sarcopenia 
so that interventions can be explored that may help slow the acceleration of sarcopenia 
and reduce adverse outcomes in older adults (72).   
 Maintaining adequate blood flow, or improving blood flow with exercise, has 
been proposed as a mechanism to enhance the delivery of nutrients to skeletal muscles in 
older adults (14,71). Previous studies have demonstrated that aging muscle exhibits a 
degree of anabolic resistance following protein (41,61) and mixed nutrient ingestion (76), 
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which has led to higher recommendations of protein intake for older adults to maintain 
net protein balance (42,70). Also, older adults exhibit age-related insulin resistance that 
impairs muscle protein synthesis (21,62,74,76). It has also been shown that the attenuated 
effects of insulin on muscle protein synthesis may be due to an impaired endothelial 
response to the vasodilatory effects of insulin (16). However, exercise seems to improve 
endothelial-dependent dilation and the subsequent anabolic effects of nutrient 
consumption in healthy older adults (16,19,20,53,67,68). For example, Timmerman et al. 
(71) demonstrated increased blood flow, muscle perfusion, amino acid delivery, and 
muscle protein synthesis after mixed nutrient intake in older adults who had completed a 
bout of aerobic exercise the night prior. Thus, acute exercise may enhance the anabolic 
response to nutrient intake in older adults by improving nutrient delivery to the muscle 
via increased blood flow and muscle perfusion. Understanding how skeletal muscle 
perfusion changes with the presence of sarcopenia may be important for both exercise 
and nutrition recommendations in older adults. 
 In a study by Cramer et al. (14), individuals who were more severely sarcopenic 
(impaired gait speed and handgrip strength) benefited less from mixed nutrient 
supplementation than those who were only moderately sarcopenic (impaired gait speed, 
but normal grip strength). Since the moderately sarcopenic subgroup demonstrated higher 
baseline handgrip and leg strength, but no differences in fat-free mass, a more robust 
blood flow to the working muscles may have existed, which could have accounted for the 
better response to oral nutritional supplementation (14). Alternatively, the individuals 
who were more severely sarcopenic may have had a greater degree of impaired nutrient 
delivery, and subsequently, less favorable responses to the oral nutritional 
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supplementation (14). These results emphasize the need to compare strength and blood 
flow measurements between sarcopenic and non-sarcopenic older adults, which may help 
to explain the mechanisms underlying any responses (or lack thereof) to nutritional 
interventions.  
 Sex-related differences in fatigability during leg extension tasks have been well-
explored (12,52,77). However, less is known about the effects of sarcopenia during 
skeletal muscle fatiguing (30–32). Since sex-related differences in skeletal muscle 
fatigability have been attributed to muscle size, muscle activation, fiber type properties, 
and muscle blood flow (33), it is reasonable to hypothesize that the presence of 
sarcopenia may impact muscle fatigue via similar mechanisms. Clark et al. (12) 
demonstrated differences in time to failure during a sustained submaximal leg extension 
task between men and women, where men fatigued more quickly than women. The 
authors then completed the same protocol with the addition of femoral artery occlusion, 
which subsequently eliminated the differences in time to failure between men and 
women. These findings suggest that differences in blood flow and muscle perfusion 
between men and women may contribute to differences in fatigability. If the presence of 
sarcopenia does impact the delivery of nutrients, including oxygen, to skeletal muscles, it 
is possible that sarcopenic versus non-sarcopenic individuals would respond similarly to 
the men versus women studied by Clark et al. (12). If other factors, such as muscle size, 
muscle activation, and fiber type properties can be held reasonably constant between 
sarcopenic versus non-sarcopenic groups, differences in skeletal muscle fatigability could 
be attributable to blood flow / perfusion.  
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The purpose of the present study is to compare muscle strength, size, activation, 
and tissue oxygenation between older women with and without sarcopenia during 
dynamic fatiguing leg extension bouts with high (5-RM) and low (30% of estimated 1-
RM) external loads. It is hypothesized that (a) oxygenated hemoglobin will decrease 
while deoxygenated hemoglobin and total hemoglobin will increase during the fatiguing 
task and 5-RM, (b) EMGAMP will increase and EMGMPF will decrease during the 
fatiguing task and 5-RM, and (c) patterns of response during the fatiguing task will vary 
between sarcopenia status.  
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CHAPTER II 
REVIEW OF LITERATURE 
As defined by the European Working Group on Sarcopenia in Older People 
(EWGSOP), the parameters used to identify sarcopenia include low muscle mass, and 
either low muscle strength or low physical performance (15). However, the underlying 
causes of the decreased muscle mass, strength, and physical performance are not entirely 
understood. Numerous studies have shown that compared to younger adults, older adults 
have reduced skeletal muscle mass, decreased blood flow to the periphery, decreased 
oxygen demand in the skeletal muscle, reduced glucose uptake, reduced glucose 
transporter expression, greater insulin resistance, increased fat oxidation, increased 
intramyocellular fat content, and reduced mitochondrial activity (8,9,17,56). The 
availability and oxidation of energy substrates may be impacted by any of these 
differences which in turn, may contribute to the anabolic resistance associated with aging. 
In fact, Timmerman et al. (71), found that aging is associated with a decrease in nutritive 
flow. In other words, older adults have a decreased ability to deliver nutrients to skeletal 
muscle in part due to decreased blood flow and microvascular perfusion. Additionally, 
they found that impaired nutritive flow may be attenuated by increased physical activity 
(71).  Recently the term “metabolic flexibility” has been used to describe the ability of 
individuals to switch between available substrates under various conditions (23). 
Substrate utilization has been well documented in healthy young adults at rest and during 
exercise and an ability to switch between substrates under various conditions is 
considered healthy (7,22). The effects of aging on muscle metabolic characteristics and 
blood flow have been extensively explored, interestingly, however, older adults with 
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normal muscle mass and strength/function have not yet been compared to older adults 
classified as sarcopenic (low muscle mass and strength/function).  
Due to the multi-faceted nature of sarcopenia, the etiology is poorly understood 
and difficult to define (9). One factor contributing to the increased loss of muscle mass 
with age may be nutrient insufficiency due to an inability to utilize available nutrients, an 
inability to deliver necessary nutrients, or perhaps a combination of the two. The purpose 
of this literature review is to explore the age-related changes in skeletal muscle 
metabolism, oxygenation, and blood flow and how these changes may contribute to an 
accelerated loss of muscle mass (sarcopenia).  
Changes in skeletal muscle with aging 
Bonadonna, Groop, Simonson, and DeFronzo, 1994 
 The Randle Cycle describes the competition between free-fatty acid (FFA) and 
glucose for substrates under various conditions. The purpose of this study was to examine 
insulin sensitivity in a group of nondiabetic elderly subjects and verify whether or not the 
Randle cycle is present in these individuals. Seven healthy young (four men, three 
women, mean ± SD: age = 21 ± 1 years, height = 174 ± 1.4 cm, weight = 67.4 ± 2.6 kg) 
and seven old (four men, three women, 71 ± 2 years, 171 ± 3 cm, 69.6 ± 4.3 kg) 
volunteers gave informed consent and participated in this study. Four of the older 
subjects had a nondiagnostic oral glucose tolerance. Lean body mass was determined 
using the tritiated water dilution technique. Two different euglycemic insulin clamps 
were performed in random order within 5 to 7 days. Indirect calorimetry was assessed 
during the final 60 minutes of each clamp. Blood and breathe samples were gathered at 
10-minute intervals to assess glucose, FFA, and CO2 specific activities and plasma 
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insulin concentration. Two-way repeated measures ANOVA were used to assess the 
impact of age and insulin on all variables. Bonferroni’s t test and unpaired Student’s t 
tests were used for additional comparisons. Older subjects had higher fat mass (22.7± 2.9 
kg) and body fat percent (32.4 ± 3.8%) than the young subjects (13.1 ± 2.2 kg, 19.4 ± 
3.4%), but lean body mass was not significantly different (46.9 ± 3.7 kg [old], 54.3 ± 3.3 
kg [young]). Plasma glucose concentrations were similar in the older and younger 
subjects during the basal states (4.8 ± 0.1mM [old], 5.0 ± 0.1mM [young]) and during 
both insulin clamp techniques (4.9 ± 0.2mM [old], 4.9 ± 02mM [young]). Plasma insulin 
concentrations were similar for both groups in the basal state (47.4 ± 6.6pM [old], 57.6 ± 
72 [young]), however, insulin concentrations were higher in the older (1536 ± 120 pM) 
than younger (1332 ± 72pM) subjects at higher insulin infusion rates (p = 0.16). The 
older subjects had higher basal plasma FFA concentrations, and higher FFA 
concentrations at all five insulin infusion rates. Plasma FFA utilization, oxidation, and net 
lipid oxidation rate relative to LBM were significantly greater in the older than in the 
young in all states. However, when relative to FM, there were no significant differences. 
It is unknown though, if this is purely due to the older adults having a larger source of 
adipose tissue, or if it is due to increased lipolytic activity. Hepatic glucose production 
and whole-body glucose disposal was similar between the two groups at baseline and 
during all insulin infusion rates. However, total glucose oxidation was lower in the older 
group at all time-points. The authors conclude that the combination of increased FFA 
oxidation and decreased glucose oxidation may be indicative of substrate competition and 
thus increased Randle Cycle activity.  
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Dinenno, Jones, Seals, and Tanaka, 1999 
 Evidence suggests that blood flow and vascular conductance may decrease with 
age, however, how and why this occurs is not well understood. The purpose of this study 
was four-fold: 1) to compare limb blood flow at rest in younger and older subjects, and if 
a difference exists 2) determine if it is a function of lower systemic arterial blood flow, 3) 
determine if it is due to increased sympathetic vasoconstrictor activity, and 4) determine 
if it is related to a decreased oxygen demand and tissue mass. Sixteen young (28 ± 1 
years) and 15 older (63 ± 1 years) healthy men gave informed consent and participated in 
this study. Body composition was assessed using DXA or hydrodensitometry. Femoral 
blood flow and vascular conductance were assessed using a duplex ultrasound machine. 
Vascular conductance was calculated as femoral blood flow/mean arterial pressure. 
Vascular resistance was calculated as mean arterial pressure/femoral blood flow. 
Echocardiography was used to assess stroke volume and calculate cardiac output. Muscle 
sympathetic nerve activity (MSNA) of the right peroneal nerve was assessed using a 
microneurographic technique. Leg oxygen consumption was estimated using whole-body 
resting oxygen consumption measured by indirect calorimetry (leg oxygen consumption 
= 7.5% of whole-body oxygen consumption). One-way ANOVAs and ANCOVAs were 
used to assess differences between the older and younger groups. Univariate correlation 
analysis was used to assess specific physiological variables. There were no significant 
differences in height, body mass, or leg composition between the older and younger 
groups (p > 0.05), however, the older men had higher body fat percent (25 ± 2%) and 
diastolic blood pressure (74 ± 2 mmHg) than the younger men (15 ± 2%, 65 ± 3 mmHg). 
Femoral artery blood flow was 26% lower in the older men (p < 0.005) due to lower 
 9  
mean blood velocity, as opposed to artery diameter. Older men had 32% lower femoral 
vascular conductance and 45% higher femoral vascular resistance than the younger men. 
Heart rate, stroke volume, and cardiac output were not significantly different between the 
two groups. MSNA was 74% higher in the older men than the younger men. Femoral 
blood flow (r = -0.55), vascular conductance (r = -0.65), and vascular resistance (r = 
0.61) were all significantly related to MSNA. Age-related differences in femoral blood 
flow, vascular conductance, and vascular resistance were reduced by 60%, 57%, and 
67%, respectively, after controlling for MSNA. Older men (217 ± 9 mL/min) had lower 
whole-body oxygen consumption than younger men (254 ± 8mL/min). Thus, estimated 
leg oxygen consumption was 15% lower in the older men than younger men. Femoral 
blood flow was correlated to estimated leg oxygen consumption (r = 0.78). Age-related 
differences in femoral blood flow was reduced by 50% after correcting for leg oxygen 
consumption. The results of this study suggest that reduced lower limb blood flow is due 
to elevated sympathetic vasoconstrictor activity (decreased conductance and increased 
resistance) rather than decreased cardiac output. Secondly, estimated leg consumption 
was lower in the older men, independent of leg tissue mass. The results of this study add 
to our understanding of age-related differences in hemodynamics.  
Donato, Uberoi, Wray, Nishiama, Lawrenson, and Richardson, 2006.  
 Numerous studies have documented decreased blood flow and increased vascular 
resistance in the leg in older adults, however, less data exists regarding age-related 
changes in forearm bloodflow. The purpose of this study was to examine leg and forearm 
blood flow before and during submaximal dynamic leg extensions and forearm flexions 
in older and younger adults. Eight young (20 – 29 years old) and six older (65 – 80 years 
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old) healthy males gave informed consent and participated in this study. The subjects 
performed absolute submaximal workloads and relative workloads of single leg dynamic 
extensions and rhythmic handgrip exercises. Subjects exercised for 3 minutes before 
blood flow measurements were taken to ensure steady-state had been achieved. Doppler 
ultrasound was used to measure blood flow at the common femoral artery and brachial 
artery. Leg blood flow was taken in a seated position, which is different from many other 
studies who examine blood flow in a supine position. Indirect calorimetry was used to 
calculate leg VO2 during the leg extension exercises by subtracting resting VO2. Forearm 
and thigh muscle volume were estimated using circumference and skinfold 
measurements. Two-factor mixed model ANOVAs were used to assess the impact of age 
and exercise intensities. Wilcoxon’s and Freidman nonparametric tests were also used. 
The older group had a significantly higher BMI (27 ± 2 kg/m2), systolic and diastolic 
blood pressure (129 ± 7/ 82 ± 10), and heart rate (70 ± 7 bpm) than the younger group (24 
± 3 kg/m2, 119 ± 11/ 70 ± 8, 62 ± 8 bpm). The older group had significantly lower 
quadriceps muscle mass (1.6 ± 0.1 kg) than the younger group (2.1 ± 0.2 kg), but forearm 
muscle mass was similar between the two groups (0.84 ± 0.2 vs. 0.97 ± 0.1 kg). 
Additionally, the older group had significant lower maximal handgrip strength (28 ± 6 
kg) and knee extensor strength (31 ± 17 W) than the younger group (51 ± 5 kg, 61 ± 11 
W). Seated resting leg blood flow was 26% lower in the older adults but was not different 
when expressed per kilogram of quadriceps muscle mass. Resting arm blood flow was 
not different between the two groups in relative or absolute terms. At all absolute 
submaximal leg extension intensities, relative leg blood flow was similar between young 
and older subjects. However, for relative workloads older adults had decreased relative 
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blood flow compared to younger adults. Relative leg VO2 was similar between the two 
groups under both absolute and relative workloads. Absolute and relative forearm blood 
flow was similar between young and old subjects at absolute workloads. The authors 
concluded that their leg blood flow results seemed to be much lower than previous 
studies findings, which indicates the importance of position while taking blood flow 
measurements. Additionally, this paper helps aid in our understanding peripheral limb 
blood flow and the differences that may exist between the upper and lower body.   
Nilwik, Snijders, Leenders, Groen, Kranenburg, Verdijk, et al., 2013 
There has been some debate on whether loss of muscle mass with aging is due to 
muscle fiber loss or muscle fiber atrophy. The purpose of this study was to determine if 
differences in muscle cross-sectional area (CSA) between young and older men are 
mainly due to differences in muscle fiber size. Furthermore, a secondary purpose was to 
determine if increases in muscle mass in older adults after a resistance training program 
were due to muscle fiber hypertrophy. Twenty-five healthy young (23 ± 1 year) and 26 
healthy old (71 ± 1 year) participated in this cross-sectional study, the old group also 
participated in 6-month resistance training program. Whole-body DXA scans, thigh CT 
scans, and vastus lateralis muscle biopsies were performed at baseline for both groups 
and additional after the training program for the old group. Muscle biopsies were used to 
determine the relative percentage of type I and type II muscle fibers, and these 
percentages were used to determine the CSA occupied by each fiber type. Exercises 
included leg press, leg extension, chest press, horizontal row, lateral pull down, and 
biceps curl. One-repetition strength tests for leg press and leg extension were used at 
baseline and repeated every 4 weeks until the end of the training program. Independent 
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samples t-tests were used to determine difference between young and old men for all 
variables. Paired samples t-tests were used to determine differences in strength and CSA 
in the old men from pre- to post-training. A repeated measures ANOVA was used to 
determine changes in fiber size in the old men from pre- to post-training with fiber type 
as a within-subjects factor. Correlation coefficients (r) were used to determine if muscle 
fiber size was associated with greater muscle strength in the older men at baseline and 
post-training. Whole body lean mass was not different between young (62.7 ± 1.4 kg) and 
older men (62.2 ± 1.1 kg) however, leg lean mass was lower in older men (9.9 ± 0.2 kg) 
than young (11.0 ± 0.3 kg). Additionally, quadriceps CSA was 14% smaller in older (68 
± 2 cm2) than young men (80 ± 2 cm2). Average muscle fiber size was 20% smaller in the 
older than younger men. Type II muscle fiber size was much smaller in the older (5050 ± 
198µm2) versus the young men (7136 ± 309µm2), however type I muscle fibers exhibited 
no difference in size between the two groups (p > 0.05). Consequently, absolute CSA 
occupied by type II muscle fibers was smaller in the older (29 ± 2 cm2) than younger men 
(46 ± 2 cm2). The number of muscle fibers was not different between older (119 ± 4 • 
104) and younger men (127 ± 3 • 104). After the training program, older men exhibited a 
1.7 ± 0.4% increase in whole body lean mass and a 3.2 ± 0.7% increase in leg lean mass 
(p < 0.05) and CSA significantly increased from 68±2 to 74±2 cm2). Additionally, leg 
press and leg extension strength significantly increased by 25 ± 2 and 41± 3%, 
respectively. No changes in muscle fiber type distribution occurred. Type II muscle fiber 
size significantly increased 24 ± 8% to 6096 ± 338 µm2 (p ≤ 0.05) whereas there was no 
significant increase in type I muscle fiber size after the training intervention (p > 0.05). 
Additionally, type II muscle fibers were significantly smaller than type I in the older men 
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at baseline, however, this difference did not remain at post-training. There were no 
changes in the number of muscle fibers from pre- to post-training. Type II muscle fiber 
hypertrophy explained 100±3% of the increase in quadriceps CSA from pre- to post-
training. Baseline correlations indicated that type II muscle fiber size was significantly 
correlated with leg press (r = 0.62) and leg extension (r = 0.38). However, this 
relationship did not exist after training. The authors concluded that type II muscle fiber 
size alone can explain the differences in leg muscle CSA between young and old men. 
Additionally, type II muscle fiber hypertrophy after 6 months of resistance training 
explains the increase in thigh CSA in older men. The results of this study contribute to 
our understanding of the etiology of age-related loss of muscle mass.  
Defining the population: Sarcopenic vs. nonsarcopenic 
Currently, there is no established clinical definition of sarcopenia, which makes 
recognition and appropriate treatment a difficult feat (75). It is debated whether 
sarcopenia should refer only to age-related loss of muscle mass, or whether the definition 
should include a decrease in strength and function as well (9). The prevalence of 
sarcopenia and risk of disability may vary greatly depending on how the condition is 
identified and classified (36). The EWSOP has identified sarcopenic stages which 
identify the severity of the condition. Pre-sarcopenia is characterized by low muscle mass 
without decreased strength or physical function. Sarcopenia is characterized by low 
muscle mass with either low strength or low physical function. Severe sarcopenia is 
characterized by low muscle mass with both low strength and low physical function (15). 
The purpose of this section is to gain an understanding on the relationships between 
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physical function/strength and sarcopenia and how the severity of the condition affects 
incidence of disability and responsiveness to nutritional intervention.  
Iannuzzi-Suchich, Prestwood, and Kenney, 2002  
The purpose of this study was to determine the prevalence of sarcopenia in a 
cohort of community-dwelling older adults using the definition established by 
Baumgartner and colleagues. One-hundred ninety-five healthy women (75.0 ± 4.7 years, 
BMI 26.5 ± 51 kg/m2) and 142 healthy men (73.8 ± 5.3 years, BMI 26.5 ± 3.9 kg/m2) 
gave informed consent and participated in this study. Body composition was measured 
using whole body dual x-ray absorptiometry (DXA) scans. Appendicular (ASM) and total 
skeletal muscle mass (TSM) were adjusted for height. Sarcopenia was defined as skeletal 
muscle mass greater than two standard deviations below the sex-specific normal mean. 
Physical activity levels were estimated using the Physical Activity Scale for the Elderly. 
1RM leg press strength and power were measured in the men only. The Short Physical 
Performance Test (SPPB), Physical Performance Test, and SF-36 health survey were also 
completed to measure physical function and quality of life. Fasting blood and urine 
samples were collected to measure 25-hydroxy vitamin D (25OHD), estrone, estradiol, 
bioavailable testosterone (men only), sex hormone-binding globulin (SHBG). Pearson 
correlation coefficients were used to examine the relationship between skeletal muscle 
mass and hormone levels, physical activity, physical function, strength, and power. 
Multiple linear regression was used to determine which variables were the best predictors 
of the variance in skeletal muscle mass. Sarcopenia was prevalent in 22.6% (44) of the 
women and 26.8% (38) of the men using the definition proposed by Baumgartner and 
colleagues. A subgroup of 80+year olds were analyzed and the prevalence increased to 
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31.0% (9 out of n = 29) in women and 52.9% (10 out of n = 19) in men. BMI was 
significantly correlated with ASM in women (r = 0.695) and men (r = 0.682). Estrone (r = 
0.244), estradiol (r = 0.357), and 25OHD (r = -0.161) were significantly correlated with 
ASM in women. Leg press strength (r = 0.504) and power (r = 0.409) and bioavailable 
testosterone (r = 0.357) were significantly correlated with ASM in men. BMI accounted 
for 47.9% of the variability in ASM in women (p < 0.001). BMI (50.1%), leg press 
strength (10.3%), leg press power (4.1%), and bioavailable testosterone (2.6%) accounted 
for 67.1% of the variability in ASM in men (p <0.001). The results of this study helped 
confirm incident rates of sarcopenia based on the cut points of less than 2 standard 
deviations below the sex-specific healthy young adult average for skeletal muscle mass.  
Janssen, 2006 
Many studies examining sarcopenia are cross-sectional and therefore it is 
unknown whether sarcopenia precedes physical disability or vice versa. The purpose of 
this study was to determine if the onset of physical disability can be predicted by the 
presence of sarcopenia. Five-thousand thirty-six older men and women from the 
Cardiovascular Health Study were analyzed in this study. At baseline subjects were 
categorized by muscle mass (normal, moderate sarcopenia, or severe sarcopenia) and 
disability status (yes or no).  Follow-up examinations were used to understand the 
relationships between sarcopenia and disability in the 3,694 subjects who were not 
disabled at baseline. Whole body muscle mass was estimated using bioelectrical 
impedance analysis (BIA) and was normalized for height (skeletal muscle index, SMI). 
Age, race, socioeconomic status, smoking status, adiposity status, cognitive function, and 
prevalence of cardiovascular and non-cardiovascular disease were used as covariates or 
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as potential effect modifiers in subgroup analyses. Disability scores were assessed 
according to an individual’s ability to complete heavy housework, light housework, 
shopping, preparing meals, paying bills, and using the telephone. Logistic regression was 
used to determine cross-sectional odds ratios at baseline for the relationship between 
muscle mass and disability prevalence.  Cox proportional hazards regression was used to 
determine the risk of developing disability according to muscle mass. At baseline, 70.7% 
of the men and 41.9% of the women had moderate sarcopenia and 17.1% of the men and 
10.7% of the women had severe sarcopenia. Disability likelihood was significantly 
greater in the severe sarcopenia group than the normal muscle mass group (p < 0.001), 
however, the likelihood was not greater in moderate sarcopenia than normal muscle mass 
(p = 0.38).  The risk of developing disabilities was 27% greater in the severe sarcopenia 
group than the normal muscle mass group (p < 0.05). There was no significant difference 
in increase in risk of disability between the normal muscle mass group and moderate 
sarcopenia group. The authors conclude that the relationship between sarcopenia and 
disability is bidirectional.  
Cramer, Cruz-Jentoft, Landi, Hickson, Zomboni, Pereira, et al., 2016.  
 Nutritional interventions may improve muscle-related outcomes in individuals 
with sarcopenia due to the close relationship with malnutrition. The purpose of this study 
was to examine the effects of 6-month supplementation of 2 different oral nutrition 
supplements (ONS) in older adults with malnutrition and sarcopenia. Subjects were 
instructed to consume 2 servings daily between meals and continue their regular diet and 
exercise. Subjects visited the laboratory every 6 weeks to assess compliance, medication 
changes, and adverse events. Height, weight, body composition, leg strength, grip 
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strength, gait speed, and fasting blood draws were measured at baseline, 12 and 24 - 
weeks. A total of 330 subjects enrolled in this study in 8 countries across Europe and 
North America. Subjects were randomized to either control (n = 165, 625 women, mean 
[25th, 75th interquartile range]; age 77 [71, 81], weight 70 [60, 78] kg) or experimental 
ONS (n = 165, 62% women, age 77 [71, 81], weight 68 [58, 78] kg). The control ONS 
consisted of the following: 14 g protein, 11 g fat, 44 g carbohydrate, 147 IU vitamin D3, 
and additional vitamins and minerals. The experimental ONS consisted of 20 g protein, 
11 g fat, 36 g carbohydrate, 1.5g CaHMB, 499 IU vitamin D3, and additional vitamins and 
minerals. Leg extension strength (peak torque) was measured on an isokinetic 
dynamometer set at 60 degrees/second. Grip strength was measured with a calibrated 
dynamometer adjusted to grip width. Body composition was measured using dual x-ray 
absorptiometry (DXA). Muscle quality was assessed by calculating peak torque relative 
to total lean muscle mass (nm/kg). Subjects were classified as either severe sarcopenia or 
mild-moderate sarcopenia. Mild-moderate sarcopenia group was further classified as 
sarcopenia with normal gait speed or sarcopenia with normal grip strength. Wilcoxon 
rank sum test and Wilcoxon signed rank tests were used to examine between group and 
within group differences, respectively. The primary finding from this study was that 
sarcopenia staging (severe vs mild-moderate) differentially affected peak torque in 
response to ONS supplementation. In the mild-moderate sarcopenic group, greater 
increases in peak torque at 12 weeks were seen in the experimental ONS group than the 
control ONS group. In the severe sarcopenic group, increases in peak torque were seen at 
24 weeks but not 12 weeks. The authors concluded that there may be a delayed time 
course in skeletal muscle adaptations in severely sarcopenic individuals. The authors also 
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concluded that this delay may be due to physical differences between the groups at 
baseline as the severe sarcopenic group had lower lean muscle mass, peak torque, muscle 
quality, grip strength, and gait speed, and higher fat mass than the mild-moderate group. 
Furthermore, the authors hypothesized that the delayed response in the severely 
sarcopenic individuals may be due to decreased delivery of nutrients to the muscle 
(termed “nutritive flow”) due to impaired blood flow.  
Age-related reductions in metabolism related to sarcopenia  
The term “metabolic flexibility” has been coined to describe the healthy 
fluctuations of substrate utilization from fasted to fed states as well as from rest to 
exercise. An inability to switch between carbohydrate and fat oxidation under various 
conditions may, in part, be due to decreased availability of nutrients to skeletal muscle 
via decreased blood flow or impaired glucose uptake (72). The purpose of this section of 
the literature review is to gain an understanding of normal and abnormal patterns of 
substrate utilization under various conditions.  
Kelley, Goodpaster, Wing, and Simoneau, 1999 
There is significant evidence of impaired glucose uptake in response to insulin in 
obese individuals, however, less is known about substrate utilization during fasting 
conditions in obese individuals. The purpose of this study was to examine the relationship 
between fat oxidation and skeletal muscle fat infiltration and to explore the relationship 
between fatty acid and glucose utilization during fasting conditions and obesity-related 
insulin resistance. Lean (n = 16, mean ± SD: weight = 71.1 ± 2.3 kg, 18% body fat 
[male], 63.1 ± 2.7 kg, 30% body fat [female]) and obese (n = 40, weight = 108.1 ± 3.2 kg, 
31% body fat [male], 92.5 ± 3.8 kg, 42% body fat [female]) adults between the ages of 25 
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and 40 who were sedentary, glucose tolerant, and had normal blood lipid profiles 
participated in this study. Blood samples were obtained from the radial artery and femoral 
vein during a fasting period, after FFA infusion, and during a continuous insulin plus 
20% dextrose infusion. Resting blood flow of the leg was measured using venous 
occlusion strain-gauge plethysmography and a muscle biopsy of the vastus laterals was 
taken. Computed tomography (CT) was used to obtain muscle and fat cross-sectional area 
of the thigh and dual-energy X-ray absorptiometry (DXA) was used to determine fat 
mass (FM) and fat-free mass (FFM). A modified incremental Bruce protocol on a cycle 
ergometer was used to determine VO2max. Two-way analysis of variance (ANOVA) was 
used to compare obese vs. lean and men vs. women on substrate metabolism, body 
composition, and insulin sensitivity. To examine the correlations among fat mass, 
VO2max, and substrate metabolism linear regression and step-wise multiple regression 
analyses were used. The main findings from this study were that obese had significantly 
higher fasting RQ values (0.90 ± 0.02) than lean (0.83 ± 0.002), but also had significantly 
lower insulin-stimulated RQ values (0.91± 0.02) than lean (0.99 ± 0.03). Additionally, 
obese fasting RQ was not significantly different than obese insulin-stimulated RQ. 
Because of this, the authors concluded that obese individuals have a decreased ability to 
adjust between fat and glucose utilization under various conditions. Fasting FFA uptake 
was similar for lean and obese subjects, however, fasting FFA oxidation was significantly 
greater in lean than obese. Thus, net FFA storage was significantly greater in obese. 
Conversely, insulin-stimulated FFA uptake was similar for lean and obese, however, 
insulin-stimulated FFA oxidation was higher for obese than lean. CT scans of the thigh 
indicated increased lipid content within the skeletal muscle of obese individuals. 
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Additionally, fasting RQ values were significantly and negatively correlated with insulin 
sensitivity (r = - 0.57). Finally, fasting RQ and cross-sectional area of low-density muscle 
together predicted 48% of the variability in insulin-sensitivity. This was one of the 
original articles to coin the term “metabolic flexibility” and adds to our understanding of 
the term with regards to healthy, lean individuals and obese individuals.  
Bergman and Brooks, 1999 
 The purpose of this paper was to compare respiratory exchange ratios (RER) 
during various intensities of cycling in trained versus untrained men in both fed and 
fasted conditions. Seven untrained (mean ± SD: age; 22.1 ± 1.3 years, weight; 75.6 ± 6.2 
kg, % body fat; 180.0 ± 2.9) and seven trained (age; 25.1 ± 1.8 years, weight 73.7 ± 3.5, 
% body fat; 9.6 ± 1.8) healthy men gave informed consent and participated in this study. 
Progressive maximal exercise tests were completed on two different occasions to 
familiarize the subjects and determine maximal (peak) VO2 (VO2peak). Blood samples 
were taken after each workload stage to determine lactate concentrations and calculate 
lactate threshold (trained men only). Body composition was assessed using the seven-site 
skinfold method. Once VO2peak was determined, subjects were randomized to exercise 
intensity (20% [2 hours], 40% [2 hours], 60% [1.5 hours], and 80% [trained: 45 min, 
untrained: 30 min] VO2) and nutrition state (fed vs. fasted). Therefore, each subject 
completed 8 separate exercise trials. Meals were controlled the night before and morning 
of each exercise trial. RER values were determined using open-circuit calorimetry and 
total workload (kcal/minute) and relative carbohydrate and lipid oxidation rates were 
calculated. Independent sample t-tests were used to compare characteristics of trained and 
untrained men. Factorial ANOVAs were used to determine differences between absolute 
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oxidation rates of carbohydrates and lipids in trained versus untrained. Mixed model 
ANOVAs were used to determine differences in mean RER over time between groups 
(trained vs. untrained) and nutrition status (fed vs. fasted).  There were no significant 
differences in age or weight between trained and untrained subjects (p > 0.05). The 
trained men had lower % body fat and higher VO2peak (58.04 ± 1.58 ml/kg/min) than 
untrained men (38.55 ± 2.39 ml/kg/min).  Fasting RER values were significantly lower 
than fed values at 22, 40, and 59% VO2peak in trained subjects and 40 and 59% VO2peak in 
untrained subjects. RER values were lower in trained subjects than untrained subjects at 
absolute workloads in both fasted and fed states. There was an exponential relationship 
between RER and power output in both fasted and fed states. Since trained subjects only 
had decreased RER at intensities of less than 40% VO2peak, the authors concluded that 
training may increase relative lipid oxidation during lower intensity exercise only.  
Additionally, ingesting carbohydrates prior to exercise increases carbohydrate oxidation 
for intensities less than 60% VO2peak. The results of this study help us understand the 
patterns of substrate utilization and oxidation in healthy young individuals at rest and up 
to 80% VO2peak.  
Rizzo, Barbieri, Ragno, Grella, Provenzano, Villa, et al., 2005 
It is evident that changes in resting metabolic rate (RMR) and body composition 
occur with aging. However, less in known about the relationship between human 
longevity and energy expenditure. The purpose of this cross-sectional study was to 
compare RMR and respiratory quotients (RQ) in adults (< 65 years old), aged-adults (66 
– 94 years old), and long-lived adults (> 94 years old). A sample of 81 healthy females 
(adults, n = 26; aged-adults, n = 27; long-lived, n = 28) participated in this study. 
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Following IRB approval and informed consent all subjects underwent a 2-week period of 
a standard diet (50% CHO, 27% FAT, 23% PRO, 1500 kcal). Waist-to-hip ratio (WHR), 
skinfold measurements, plasma blood samples, Mini Mental State Examination, and 
indirect calorimetry was assessed and recorded for all subjects. Analysis of variance 
(ANOVA) was used to determine differences among the three study groups. Pearson 
product moment correlations, partial correlations, and multivariate linear regression was 
used to examine the relationships among variables and the strongest predictors of RMR 
and RQ. The authors reported that the subjects were not obese or malnourished, had 
plasma glucose and lipid parameters within normal range, and had normal cognitive 
function. In the whole sample, RMR was significantly correlated with age (r = - 0.561), 
WHR (r = - 0.365), fat mass (FM, r = - 0.387), and % body fat (%BF, r = - 0.240). RQ 
was significantly correlated with age (r = - 0.240), WHR (r = - 0.503), FM (r = - 0.302), 
%BF (r = - 0.483), and glucose plasma levels (r = - 0.291). Together, WHR, fat-free mass 
(FFM), and total volume of expired air (TV) predicted 40% of the variance in RMR. Age, 
WHR, FFM, and plasma glucose levels predicted 46% of the variance in RQ. VO2, 
VCO2, and fasting RQ in long-lived was higher than aged-adults, but lower than adults. 
TV and RMR in long-lived adults were greater than aged-adults, but not different from 
adults. The authors analyzed the long-lived adults separately and found RQ was 
negatively correlated with %BF (r = - 0.420), fasting plasma glucose (r = - 0.596), free-
fatty acids (FFA, r = - 0.389), and WHR (r = - 0.582) whereas RMR was only 
significantly negatively correlated with WHR (r = - 0.603). The authors concluded that 
even though there is a significant age-related decline in RMR and RQ, long-lived females 
had greater RMR and RQ than aged-females. Thus, long-lived females may have a 
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protective mechanism against metabolic age-related decline. However, this may be 
explained by differences in anthropometric measurements since the long-lived females 
had a lower BMI, FFM, and WHR than the aged-females. The results of this study 
contribute to the understanding of resting metabolism, age-related changes in 
metabolism, and body composition in older females.  
Prior, Ryan, Stevenson, and Goldberg, 2014 
 The abnormal fat and carbohydrate oxidation seen in overweight older adults with 
impaired glucose tolerance may contribute to impairments in the ability to switch fuel 
substrate selection while transitioning from rest to exercise. The purpose of this study 
was to examine differences fuel substrate selection during submaximal exercise in 
overweight older adults with and without impaired glucose tolerance. Twenty-three 
sedentary overweight men and women with impaired glucose tolerance (IGT, n = 10, age 
62 ± 3 years) and without impaired glucose tolerance (NGT, n = 13, age 63 ± 2 years) 
gave informed consent and participated in this study. Body composition was assessed via 
dual energy x-ray absorptiometry (DXA) and intra-abdominal and subcutaneous 
abdominal fat was measured using computed tomography (CT). An oral glucose 
tolerance test (75-glucose ingestion) was administered to all subjects and plasma glucose 
and insulin levels were measured over a 2-hour period. An incremental treadmill protocol 
was used to measure VO2max via indirect calorimetry. Indirect calorimetry was also used 
to measure substrate utilization during rest, after insulin-stimulation, and during 
submaximal exercise (10 minutes of steady-state treadmill exercise at 50 – 60% VO2max). 
Repeated measures ANCOVA were used to identify differences between IGT and NGT 
groups, using sex as a covariate. Correlations and multivariate regression were used to 
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determine relationships among metabolic variables. Baseline analyses indicated there 
were no differences in age, weight, or body composition between the IGT and NGT 
groups. VO2max was lower in IGT (45.0 ± 1.3 ml/kg/min) than in NGT (49.0 ± 1.2 
ml/mg/min) only when expressed relative to lean body mass. There was no significant 
difference in RER between IGT and NGT at rest, however, during submaximal exercise, 
RER was significantly greater in NGT than IGT.   Indicating that the NGT group was 
better able to switch from primarily fat oxidation to carbohydrate oxidation during 
exercise. The authors conclude that older overweight individuals with glucose intolerance 
have an inability to efficiently switch between fuel substrates from rest to exercise may 
limit the ability to provide sufficient nutrients to the working muscles.  
Near-infrared spectroscopy (NIRS) as a measurement of blood flow and skeletal 
muscle metabolism with sarcopenia 
 NIRS has been used as tool to measure microvascular perfusion under numerous 
conditions. Soares et al. (2018) recently demonstrated the sensitivity of NIRS with its 
ability to detect differences in vascular responsiveness between obese and healthy lean 
individuals (69) . Additionally, numerous studies have used NIRS devices to examine 
oxygen recovery kinetics following varying modes of exercise in patients with 
cardiovascular, pulmonary, or neurological diseases (43,49,55,58). The purpose of the 
following section of the literature review is to gain an understanding of NIRS as a tool of 
measuring muscle microvascular perfusion.  
Timmerman, Dhanani, Glyn, Fy, Drummond, Jennings et al. 2012.  
 The purpose of this study was to determine if increases in physical activity 
improves muscle protein anabolism after essential amino acid (EAA) and sucrose intake 
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in older adults. Six healthy, sedentary older adults (age 70 ± 4 years) gave informed 
consent and participated in this study. Each subject completed two identical 
EAA+sucrose ingestions separated by 4 – 6 weeks. The night before one of the 
ingestions, subjects completed a 45-minute bout of aerobic exercise on a treadmill at 60 – 
70% of their heart rate reserve, the night before the other ingestion, no exercise was 
completed. During the test visit, over a three-hour period, 30 mL of EAA+sucrose was 
ingested every 10 minutes. Leg blood flow was assessed using Doppler ultrasound. 
Contrast enhanced ultrasound imaging was used to measure blood perfusion into the 
vastus lateralis. Blood samples from the femoral vein and muscle biopsies of the vastus 
lateralis were also taken. Paired t-tests were used to compare basal values between 
conditions (exercise vs. no exercise), to compare basal values to treatment values (infused 
EAA+sucrose) in each condition, and to compare change scores (EAA+sucrose – 
baseline) between the two conditions. There were no differences any baseline 
measurements between the control and exercise conditions. Blood flow was increased 
significantly more from baseline after EAA+sucrose ingestion in the exercise condition 
than control (p < 0.05).  Microvascular perfusion increased significantly from baseline to 
EAA+sucrose infusion in the exercise group only. There were no baseline differences in 
insulin and glucose kinetics between the control and exercise conditions. Insulin and 
glucose concentrations and leg glucose uptake increased significantly during 
EAA+sucrose consumption under both conditions. Endogenous glucose production 
decreased after nutrient consumption in both conditions. Phenylalanine concentrations 
significantly increased after nutrient consumption under both conditions. Phenylalanine 
delivery to the leg, output from the leg, transport into the muscle, transport out of the 
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muscle, and intracellular availability increased after nutrient consumption in both 
conditions. Additionally, phenylalanine rate of appearance, rate of disappearance, and 
utilization for protein synthesis significantly increased after nutrient consumption only in 
the exercise condition. The change scores for phenylalanine delivery to the leg, rate of 
disappearance, and utilization for protein synthesis were greater in the exercise group 
than control group. The authors concluded that an acute bout of moderate aerobic 
physical activity enhances the anabolic response to the consumption of amino acids and 
carbohydrates in older adults, due to an increase in blood flow, microvascular perfusion, 
and amino acid delivery to the working muscles. In the control condition, consumption of 
amino acids and carbohydrates alone was unable to increase muscle protein synthesis, 
blood flow, and microvascular perfusion. The results of this study add to our 
understanding of the importance of blood flow for nutrient delivery in healthy older 
adults.  
Martin, Mumford, Haun, Luera, Muddle, Colquhoun, et al., 2017 
 The purpose of this study was to determine the effects of a post-workout 
supplement on the hyperemic response following leg extension exercise at 80% and 30% 
1-repetition maximum. Thirty healthy trained males (mean ± SD: age = 22.1 ± 3.5 years, 
weight = 86.0 ± 9.5 kg) gave informed consent and participated in this study which 
included three separate visits to the laboratory. On visit one, subjects were assigned to 
placebo (PLA, maltodextrin and glycine) or pre-work out supplementation (PWS) and 
instructed to supplement for 7 days leading up to visit two. During visit two, blood 
samples, heart rate, blood pressure, and femoral artery blood flow were measured at rest, 
45-minutes post-supplement consumption, and 5 minutes post-exercise. The subjects then 
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consumed their supplement, rested for 45 minutes and then completed the leg extension 
protocol (40 sets of dynamic bilateral leg extension to failure at 30% or 80% 1RM). 
During the exercise, a NIRS device was placed on the left vastus lateralis to measure 
minimum and maximum oxygenated hemoglobin (O2Hb), deoxygenated hemoglobin 
(HHb), difference between O2Hb and HHb (HbDiff), and total hemoglobin (tHb). Visit 
three was also preceded by 7 days of supplementation and was identical to visit two 
expect subjects completed the opposite training load (30% or 80%). Independent t-tests 
were used to examine baseline differences between groups. Three-way (time x group x 
load) mixed model ANOVAs were used to examine all dependent variables. There were 
no significant differences in baseline characteristics between PLA and PWS (p > 0.05). 
There was no difference between final volume load (sum of all four sets) between 80% 
and 30% loads. Significantly lower max tHb and min O2Hb in the 80% load condition 
than the 30% load condition were observed during the first set of leg extension exercises. 
The authors concluded that this suggested oxygen consumption and metabolic demand 
was greater than blood perfusion to the working muscle. The results of this study aid in 
our understanding of the effects of leg extension exercise on variables measured with 
NIRS.  
de Oliveira, Morgado, Conte-Junior, and Alvares, 2017 
 The purpose of this study was to determine if beetroot-based nutritional 
supplement promotes muscle oxygenation, blood volume, and muscle strength in the 
forearm after fatiguing handgrip exercise. Twelve healthy older adults (n = 3 male, n = 9 
female; age = 68.8 ± 3.5 years) provided informed consent and completed this 
randomized, double-blind, crossover design study. Each subject visited the laboratory 3 
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times for a familiarization trial, then two experimental trials (placebo and beet-root), with 
a one-week wash out period between all visits. All subjects consumed 100g of a beetroot 
based nutritional gel (BG) or a nitrate-depleted placebo gel (PLA). Urine samples were 
obtained at baseline, and 90, 150, and 180 minutes after supplementation intervention to 
measure urinary nitrite and nitrate. Approximately 150 minutes after supplementation 
intervention, a near-infrared spectroscopy (NIRS) device was placed on subjects anterior 
forearm and they began the handgrip exercise protocol. The exercise protocol consisted 
of one minute of rhymic contractions at 30% MVC. Tissue saturation index (TSI%) and 
blood volume (tHb) were measured with the NIRS at baseline, during forearm exercise, 
and during exercise recovery. Minimum TSI%, half-desaturation time, desaturation rate, 
resaturation rate, and blood volume amplitude during exercise (ΔtHbEx) and exercise 
recovery (ΔtHbRec) were calculated. A paired t-test was used to determine differences in 
desaturation rate, resaturation rate, ΔtHbEx, and ΔtHbRec between BG and PLA. A two-
way repeated measures ANOVA was used to determine differences in TSI%, tHb, muscle 
strength, nitrite, and nitrate between BG and PLA. Urinary concentrations of nitrite and 
nitrate were greater at T150 and T180 in BG than PLA. Resaturation rate and ΔtHbRec 
were significantly greater in BG (1.43 ± 0.77 %•s-1, 10.25 ± 5.47 μM) than PLA (1.02 ± 
0.48 %•s-1, 6.72 ± 4.55 μM). Minimum TSI% was lower in BG (-13.68 ± 6.77 %) than 
PLA (-10.70 ± 5.02%). There were no differences in decrease in MVC (ΔMVC) 
immediately following the fatiguing exercise between PLA (-0.77 ± 0.45 N) and BG (-
0.71 ± 0.40 N). However, after 30 minutes of recovery, ΔMVC was lower in BG (- 0.24 ± 
0.18 N) than PLA (-0.39 ± 0.20 N). The authors conclude that BG supplementation 
increased muscle oxygen extraction, muscle resaturation rate following exercise, and 
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force recovery in the forearm muscles following a fatiguing exercise in older adults. This 
suggests that the supplementation was able to increase nitric oxide bioconversion in the 
muscle, thus improving the vasodilatory effect and improving blood and oxygen delivery 
to the active muscle. The results of this study aid in our understanding of blood 
oxygenation and blood volume measurements in older adults as measured with the NIRS 
device.  
Niemeijer, Jansen, Van Dijk, Spee, Meijer, Kemps et al., 2017 
 NIRS devices that utilize spatially-resolved spectroscopy offer an effective tool to 
monitor muscle microvascular oxygen function, however, the effects of adipose tissue 
thickness (ATT) are often underestimated. The purpose of this study was to explore the 
extent to which subcutaneous adipose tissue effects NIRS derived measurements in vivo 
and in vitro using a blood phantom device to isolate the effects of adipose tissue 
thickness. Fifty-six subjects with chronic heart failure (CHF, n = 49 male, n = 7 female, 
age 64 ± 9 years, weight 86 ± 15 kg) and 20  healthy active individuals (n = 16 male, n = 
14 female, age 63 ± 6 years, weight 85 ± 14 kg) gave informed consent and completed 
this study. All subjects completed a maximal ramp exercise protocol on a cycle ergometer 
to calculate peak work rate, peak VO2, peak respiratory exchange ratio (RER), and the 
gas-exchange threshold (GET). Submaximal exercise tests consisted of a 6-minute bout at 
80% of the work rate corresponding to the GET, or 50% fo the peak work rate. A NIRS 
device was placed on the vastus lateralis during the cycling exercise to measure tissue 
oxygen saturation (StO2), tissue saturation index (TSI%), and deoxygenated hemoglobin 
(HHb). Adipose tissue thickness was measured using a skinfold caliper. To measure the 
effects of ATT in vitro, the NIRS device was placed on a blood mixture with known 
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concentration without no layer of porcine fat, then with 8 consecutive measurements of 
increasing porcine fat thickness (2 mm up to 14 mm). Independent t-tests and Mann-
Whitney U tests were used to compare CHF and healthy groups. Pearson correlation 
coefficients were used to examine the relationships between the NIRS measurements and 
potential confounding factors (age, gender, ATT, etc.). Multivariate linear regression was 
used to determine the best predictors of the NIRS variables. ATT had the strongest 
correlation with with all NIRS variables (r2 = 0.098 – 0.393) than any other variables 
(gender, age, CHF). Additionally, in vitro measurements indicated that adding adipose 
tissue up to 14mm resulted in a ecrease of TSI to 73.5% for 100% SO2, and a TSI of 68% 
for 0% SO2. The average absolute deviate was approximately 5%. Thus, it appears that 
adipose tissue thickness underestimates oxygenation, and overestimates deoxygenation. 
The results of this study emphasis the importance of correcting for adipose tissue 
thickness when comparing NIRS parameters between subjects.   
Soares, Reimer, Alenezi, Doyle-Baker, and Murias, 2018 
 The purpose of this study was to determine if near-infrared spectroscopy (NIRS) 
is able to detect differences in vascular responsiveness following an oral-glucose 
tolerance test between obese and lean individuals. Fifteen lean individuals (n = 9 males, n 
= 6 females, age: 25.2 ± 1.2 years, BMI: 21.3 ± 1.7 kg/m2) and 13 obese individuals (n = 
10 males, n = 3 females, age: 23.4 ± 1.1 years, BMI: 34.4 ± 2.0 kg/m2) gave informed 
consent and participated in this study. Vascular responsiveness and blood glucose 
measurements were taken at baseline, and 30, 60, 90, and 120 minutes after ingesting 75 
g of glucose. Vascular responsiveness was measured with NIRS during vascular 
occlusion tests (VOT). NIRS device was placed on the tibialis anterior and a pneumatic 
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cuff attached to a rapid inflation system was placed just below the knee. Five minutes of 
baseline was collected, followed by 5 minutes of occlusion at 250 mmHg, and finally 20 
minutes of recovery. Baseline oxygen saturation (StO2, %), StO2 resaturation rate (%•s-1), 
and StOs area under the curve (StO2AUC) were reported. One-way repeated measures 
ANOVAs were used to examine differences between lean and obese. Blood glucose 
levels were not different between lean and obese individuals at baseline. At 120 minutes 
after ingesting glucose, glucose levels returned to baseline levels in the lean group, but 
not the obese group. Glucose levels were significantly greater in the obese than lean at 90 
and 120 minutes post-glucose ingestion. Resaturation was greater in lean than obese at 90 
minutes post-glucose ingestion. However, at 120 minutes post glucose ingestion, 
resaturation rate returned to baseline values in the lean but remained elevated in the obese 
compared to baseline values. The authors concluded that the NIRS device was sensitive 
enough to detect differences in vascular responsiveness between obese and lean 
individuals. The results of this study support the use of NIRS as a tool to measure 
vascular responsiveness via muscle oxygen saturation and resaturation rate after 
occlusion 
Overall, the age-related declines in muscle mass, strength, and physical function 
are apparent. However, due to the complexity of the aging process, the mechanisms 
underlying the anabolic resistance that is associated with aging are less clear. The use of 
near-infrared spectroscopy as a measure of microvascular perfusion may provide insight 
into the issue of nutritive flow impairments in older adults. Furthermore, comparing 
otherwise healthy older adults with normal muscle mass to those with low muscle mass 
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and function may provide insight into the mechanisms that contribute to the accelerated 
loss of muscle mass with aging.  
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CHAPTER III 
METHODOLOGY 
Subjects and Research Design 
 This project is a part of a larger study funded by Abbott Nutrition entitled, “A 
pilot study to explore muscle energy metabolism and metabolic flexibility in older men 
and women.” Five sarcopenic and six non-sarcopenic females aged 65 and older were 
recruited from the Lincoln community with the use of flyers and verbal recruitment for 
this cross-sectional study.  
 To be eligible for participation, subjects did not have any of the following 
active/treated (under physician care) diseases: metabolic, hepatic, cardiovascular, 
gastrointestinal, renal, respiratory, neuromuscular diseases, or any active malignancies as 
self-reported on a health history questionnaire. They did not have any current infections, 
any chronic, contagious, infectious diseases (i.e., HIV, hepatitis A), any recent 
unexplained weight loss (i.e., 10 lbs. over the past 6 months), or any history of any 
significant neurological or psychiatric disorders (i.e., eating disorders, substance abuse, 
dementia). Subjects were not currently participating in any regular resistance training 
exercises. Subjects were able to walk without assistance (excluding use of walker or 
cane) and were classified as low- or moderate-risk as assessed by the American College 
of Sports Medicine (ACSM) Health/Fitness Facility Pre-Participation Screening 
Questionnaire. All subjects had a body mass index (BMI) of greater than 20.0, but less 
than 39.0 kg/m2, were not current smokers (within the past 10 years) and were not taking 
any medications or dietary supplements that could profoundly modulate metabolism (i.e., 
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progestational agents, steroids, growth hormone). Multi-vitamins and minerals and 
topical steroids were exceptions.  
All subjects visited the laboratory twice to complete a screening visit and a test 
visit separated by 4 to 10 days. During the screening visit, all testing procedures were 
explained to potentially eligible subjects, and they signed an approved informed consent 
document. Anthropometrics (height [cm], weight [kg) were measured, exercise risk 
stratification was determined using ACSM’s pre-participation screening questionnaire, 
and a self-reported medical history (including list of current medications) was obtained. 
Body composition, handgrip strength, gait speed, a test for post-occlusive resting 
hyperemia (PORH), and a five-repetition maximum (5-RM) test for leg extension 
strength was also measured or performed during the screening visit. During the testing 
visit, qualified subjects completed one set of submaximal, unilateral leg extension 
exercises (30% of estimated 1-RM) to volitional exhaustion with the right leg. During the 
5-RM and fatiguing leg extension exercises, surface electromyography (EMG) and near-
infrared spectroscopy (NIRS) measurements were recorded from the surface of the skin 
over the right vastus lateralis muscle.  
This study was a non-randomized, cross-sectional pilot study designed to compare 
muscle size, strength, activation, and tissue oxygenation during a 5-RM bout and a 
fatiguing bout of dynamic constant external resistance leg extension muscle actions in 
sarcopenic versus non-sarcopenic women. The independent variable in this study is 
sarcopenia status (sarcopenic vs. non-sarcopenic). Descriptive dependent variables used 
to compare sarcopenic vs. non-sarcopenic mean values included demographics, body 
composition, muscle size, muscle strength, muscular endurance, and functionality. The 
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descriptive outcome variables assessing demographics are age, height, and weight. Body 
composition assessments included percent body fat, fat mass, fat-free mass, and relative 
skeletal mass index, while muscle size assessments included muscle cross-sectional area, 
muscle thickness, adipose tissue thickness, and echo intensity. Muscle strength and 
endurance assessments are absolute leg extension strength, repetitions to failure during 
the leg extension fatiguing task, and handgrip strength, while functionality was assessed 
with gait speed. The primary dependent variables in this study assessed muscle activation 
and muscle tissue oxygenation from the vastus lateralis muscle during the 5-RM bout and 
fatiguing bout of leg extension muscle actions. The specific dependent variables 
assessing muscle activation are EMG amplitude (EMGRMS) and EMG center frequency 
(EMGMPF), while the variables assessing muscle tissue oxygenation are tissue saturation 
index (TSI%), total hemoglobin (THb), oxygenated hemoglobin (O2Hb), deoxygenated 
hemoglobin (HHb), and the difference between oxygenated and deoxygenated 
hemoglobin (HBDiff).   
Descriptive Assessments 
Demographics. Age was calculated from each participant’s self-reported 
birthdate. Height and weight were measured on a calibrated digital scale with attached 
stadiometer (Seca gmbh & co., Hamburg, Germany, Model: 769 1321994). 
Body Composition. Total body skeletal muscle (TBSM) and appendicular skeletal 
muscle (ASM) was assessed using dual-energy x-ray absorptiometry (DXA) (Lunar 
iDXA, GE Healthcare, Madison, WI). Before all scans, the device was calibrated daily 
using a quality assurance phantom that consists of varying bone mineral density and 
percent fat standards (Lunar iDXA User Manual, GE Healthcare, Madison, WI). Scans 
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were performed after at least eight hours of fasting. Before each scan, the subjects’ 
height, weight, sex, birthdate, and race was entered into the enCORE software (GE 
Healthcare, Version 14) by a licensed technician (JTC). Subjects’ bodies were free from 
all external metal objects, while internal metal devices (except pacemakers) were noted. 
Subjects laid supine on the padded scanner table with their hands pronated and near their 
body, but without touching the hip. A Velcro strap was wrapped just proximal to the 
ankles to keep the subject’s legs adducted. The appropriate thickness (thin, standard, or 
thick) based on chest depth was selected prior to completing each total-body scan (Lunar 
iDXA User Manual, GE Healthcare, Madison, WI).  
 To classify sarcopenic status, the results from the DXA scan were divided into 
axial and appendicular regions of interest to determine TBSM, ASM, and total fat mass 
(15). The right and left arms were separated from the axial skeleton through the necks of 
the humeri, while the legs were separated from the axial skeleton through the necks of the 
femurs. ASM was calculated as the sum of the lean masses calculated by the DXA 
software from the left and right arms and legs. TBSM was predicted using the equation 
developed (R2 = 0.96, SEE = 1.58 kg) by Kim et al. (44), where females = 0: 
TBSM = (1.13*ASM) – (0.02*Age) + (0.61*sex) + 0.97   (Eq. 1) 
 Relative skeletal muscle index (RSMI, %), absolute skeletal muscle mass index 
(SMI, kg·m-2), and an adjusted lean mass (ALM, kg) were also calculated for sarcopenia 
classification. RSMI was calculated using the following equation established by Janssen 
et al. (37): 
RSMI = (TBSM ÷ body mass in kg) x 100     (Eq. 2) 
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SMI was calculated using the following equation established by Baumgartner et 
al. (5): 
SMI = ALST ÷ (height2 in m)      (Eq. 3) 
ALM was calculated using the following sex-specific equations established by 
Newman et al. (54), where FM = fat mass: 
ALM (women) = -13.19 + (14.75 × height in m) + (0.23 × FM in kg) (Eq. 4) 
Using the above equations, subjects were defined as sarcopenic at screening if 
their values fell below any 1 of 4 cut-off models: (a) RSMI ≤ 28% (37), (b) SMI < 5.45 
kg·m-2 (5), (c) SMI < 5.67 kg·m-2 (54), or (d) ALM < - 1.73 kg (54). 
Using the same total-body DXA scan to classify sarcopenic status with the 
variables in Equations 1 – 4, fat mass (FM), fat-free mass (TBSM), and percent body fat 
were calculated by the enCORE software, recorded, and used in all subsequent statistical 
analyses.  
Muscle Size. A portable, brightness mode (B-mode) ultrasound imaging device 
(GE Logiq e, USA) with a multi-frequency linear array probe (12L-RS; 5–13 MHz; 38.4 
mm field-of-view) was used to determine muscle cross-sectional area, muscle thickness, 
and echo intensity of the leg extensor muscles. Subcutaneous adipose tissue thickness 
was also determined from the muscle thickness ultrasound assessment (1,39). During the 
screening visit, subjects laid supine on a padded plinth with legs extended, relaxed, and 
feet secured with a Velcro strap. A generous amount of water-soluble transmission gel 
was applied to the skin to enhance acoustic coupling and reduce near field artifacts. 
Minimal pressure necessary was applied to the probe to limit compression of the adipose 
tissue and skeletal muscle. For leg extensor muscle cross-sectional area, panoramic 
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ultrasound images were taken at 50% of the distance from the ASIS to the medial, 
superior border of the patella (beginning laterally, working medially) using GE Logiq e 
LogiqView softwareTM (46). For vastus lateralis muscle thickness, subcutaneous adipose 
tissue thickness, and echo intensity transverse images were taken at 66% of the distance 
between the ASIS and the lateral border of the patella (location of the EMG electrode) 
and immediately proximal to the EMG electrode at the location where the NIRS device 
was placed. All images were taken using the musculoskeletal mode using a gain of 58 dB 
and a frequency of 10 MHz. These settings were held constant between subjects; 
however, the depth was adjusted according to each subject’s leg size, but still held 
constant within each subject. Images were taken until three panoramic and three 
transverse scans with acceptable quality were obtained as determined by the tester 
(BDM). All images were taken prior to any exercise.  
 All images were analyzed in Image-J Software (National Institutes of Health, 
USA, Version 1.51s). Each image was scaled from pixels to cm using the straight-line 
function in Image-J prior to analyses. To determine leg extensor muscle cross-sectional 
area, the region of interest was selected using the polygon function to include as much of 
the muscle as possible, while avoiding surrounding fascia and adipose tissue. Muscle 
thickness of the leg extensor muscles and overlying subcutaneous fat thickness was 
determined using the straight-line function. Echo intensity (EI) of the leg extensor 
muscles was determined using the polygon function and a computer-aided gray-scale 
analysis. The mean EI was reported as a value between 0 (black) and 255 (white) 
arbitrary units (a.u.).  
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Muscle Strength, Endurance, and Functionality. Subjects completed a 5-RM 
unilateral, dynamic constant external resistance leg extension test on a commercially-
available, plate-loaded leg extension device (Hammer Strength Plate-Loaded, Iso-Lateral 
Leg Extension Machine; LifeFitness, Rosemont, IL, USA). Subjects were seated with 
restraining straps over the pelvis, trunk, and contralateral thigh. They were asked to sit 
with their back against the chair and hands firmly grasped on the handles near their hips. 
The lateral epicondyle of the right femur was aligned with the axis of rotation of the leg 
extension device. Subjects performed a brief warm-up set of 10 repetitions with 4.5 kg 
external resistance to familiarize with the movement. Based on the performance during 
the first set and after a 2-minute rest period, an appropriate weight was added to elicit 
failure after the fifth repetition. The 5-RM was considered successful if the subject was 
able to complete five repetitions throughout the full range of motion, but not a sixth 
repetition. A trial-and-error process was used with external resistance added or subtracted 
to reach the 5-RM trial. A minimum of two minutes and maximum of 5 minutes rest was 
allowed between attempts. Upon determination of the 5-RM, the external resistance was 
recorded and used to estimate the one-repetition maximum (1-RM) using the following 
equation (r = 0.994)(63): 
1-RM = 1.0970 X (5-RM loaded resistance in kg) + 14.2546  (Eq. 5) 
 During the test visit, the same leg extension device was loaded with an external 
resistance equal to 30% of the estimated 1-RM (rounded to the nearest 1.2 kg) to 
complete the submaximal, fatiguing leg extension exercise task. Subjects completed 
dynamic, unilateral leg extension exercises until volitional failure (66). A metronome was 
set to 20 beats per minute, so that one repetition was completed approximately every 3 
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seconds. The number of repetitions completed was recorded as an assessment of muscle 
endurance. For surface EMG and NIRS data analysis, five individual repetitions were 
selected for analysis that corresponded with approximately 25% completion of the total 
fatiguing task. Specifically, the first and last repetitions, plus the closest repetitions 
corresponding to 25%, 50%, and 75% of task failure, were selected. For example, if 20 
repetitions were completed, then repetitions 1, 5, 10, 15, and 20 were selected for analysis. 
 For all leg extension muscle actions, linear force (N) was recorded from a load 
cell (Omegadyne, model LCHD-500, 0–500 lbs; Stamford, CT, USA) custom fitted 
between the shin pad and lever arm of the leg extension device. During testing and 
exercise, the subjects were seated on the leg extension machine with a strap securing their 
pelvis. The axis of rotation of the lever arm was aligned with the lateral epicondyle of the 
femur of the dominant leg. The lever arm length (m) from the fulcrum to the shin pad was 
measured and used to calculate torque (Nm). The force signal was sampled at 1 kHz with 
a Biopac data acquisition system (MP150WSW, Biopac Systems, Inc., Santa Barbara, 
CA, USA), recorded on a personal computer, and processed off-line with custom written 
software (Labview v. 12.0, National Instruments, Austin, TX, USA). Torque values were 
calculated from the signal epochs corresponding to the 60° range of motion occurring 
between 100° and 160° of leg extension (180° = full extension) during the concentric 
portion of each repetition based on the position of the lever arm monitored by a triaxial 
accelerometer (TSD109C1, Biopac Systems, Inc., Santa Barbara, CA) attached at the 
location of external load placement. 
Maximal isometric handgrip strength of the dominant hand was measured with a 
standard handgrip dynamometer with adjustable grip width (Hydraulic Hand 
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Dynamometer, Jamar Technologies, Inc, Hatfield, PA). Subjects were instructed to 
perform the handgrip strength test in a standing position facing the investigator. Subjects 
were asked to keep the arm adducted, forearm flexed to 90˚, and neutral (semi-pronated) 
grip position (2). Subjects were given three attempts to perform a maximal handgrip 
contraction, and the average force (kg) of the two highest attempts was used as a 
representation of handgrip strength and sarcopenic classification. A score of < 20 kg was 
required for classification as sarcopenic (48).  
A handheld stop watch was used to time the subjects during the gait speed 
assessment. Subjects were asked to walk at their normal walking speed on a 4-meter, 
straight, level course. Subjects were allowed to use walking aids (i.e., canes, walkers); 
however, no assistance was provided by the tester (BDM). The fastest of two trials was 
recorded. A gait speed of ≤ 0.8 m·s-1 on the 4-meter course was considered low-gait 
speed for sarcopenic classification.  
Surface Electromyography 
A pre-amplified, bipolar active electrode pair (TSD150B, Biopac Systems, Inc., 
Santa Barbara, CA) was placed over the vastus lateralis muscle of the right thigh. A 
single-differentiated, difference EMG signal was recorded from the surface of the skin 
during all leg extension exercises. The center of the electrode pair was placed at 66% of 
the distance between the anterior superior iliac spine and the superior, lateral border of 
the patella (25). The longitudinal axis of the electrode pair was angled at 20° relative to 
the longitudinal axis of femur to mimic the pennation angle of the muscle fibers (40). The 
electrode has a center-to-center inter-electrode distance of 20 mm, gain of 330 (nominal), 
input impedance of 100 MΩ, common mode rejection ratio of 95 dB (nominal), and a 
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bandwidth of 12 – 500 Hz. A single pre-gelled electrode (EL503, Biopac Systems Inc., 
Santa Barbara, CA) was placed on the tibial tuberosity to serve as the reference electrode. 
Prior to placing the electrodes, the local skin areas were prepared by light dry shaving, 
light abrasion with a cotton towel, and cleaning with isopropyl alcohol to reduce inter-
electrode impedance and improve signal to noise ratio (29).  
EMG (μV) signals were sampled at 1 kHz with a Biopac data acquisition system 
(MP150, Biopac Systems, Inc., Santa Barbara, CA). All signals were stored on a personal 
computer and processed offline with custom written software (LabVIEW v. 17.0, 
National instruments, Austin, TX). EMG amplitude (EMGRMS) was expressed as the root 
mean square value, and EMG mean power frequency (EMGMPF) was expressed in Hz. 
EMGRMS and EMGMPF were calculated for the surface EMG signal epochs corresponding 
to the 60˚ range of motion occurring between 100° and 160° of leg extension (180° = full 
extension) during the concentric portion of each leg extension repetition. Position of the 
lever arm was monitored by a triaxial accelerometer (TSD109C1, Biopac Systems, Inc., 
Santa Barbara, CA) attached at the location of external load placement. To quantify 
EMGMPF each signal epoch was processed with a Hamming window and a discrete 
Fourier transformation (DFT) based on the recommendations of Diemont et al. (78) and 
calculated as described by Kwatny et al. (47). The absolute values of EMGRMS and 
EMGMPF during the fatiguing leg extension exercises were normalized as a percentage of 
the first repetition of the 5-RM trial. Consequently, EMGRMS and EMGMPF are expressed 
as a %5-RM during the fatiguing leg extension exercises, with the first repetition of the 5-
RM equaling 100% for every subject.  
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Near-infrared Spectroscopy (NIRS) 
 A portable, continuous wavelength NIRS device (PortaMon MKII, Artinis, 
Einsteinweg 17, Netherlands) was positioned over the right vastus lateralis muscle 
immediately proximal to the EMG electrode pair (45). Prior to placement, the local skin 
area was prepared by light dry shaving, light abrasion with a cotton towel, and cleansed 
with isopropyl alcohol. The device was secured to the skin with dark-colored, opaque 
self-adherent CobanTM wrap (3MTM, Maplewood, MN, USA), which limited extraneous 
light interfering with the sensor. The NIRS device measures relative changes from baseline 
(rest) in oxygenated hemoglobin (O2Hb) concentration, deoxygenated hemoglobin (HHb) 
concentration, total hemoglobin (tHb = O2Hb + HHb), and tissue saturation index (TSI% = 
[O2Hb/tHb]*100) within a 2.0-cm tissue depth from the surface of the skin (45). Spatially-
resolved spectroscopy with a sampling rate of 10 Hz is used by the NIRS device based on 
light absorbance at 760 and 850 nm using the modified Lambert-Beer Law (65). All NIRS 
variables were calculated as the average during the signal epochs corresponding to the 
60˚ range of motion occurring between 100° and 160° of leg extension (180° = full 
extension) during the concentric portion of each leg extension repetition. 
 During the screening visit, a post-occlusion reactive hyperemia (PORH) procedure 
was used as a physiological calibration to account for inter-individual variations in NIRS 
measurements between subjects. The PORH procedure was performed while the subject was 
at rest, laying supine on a plinth with the NIRS device secured over the vastus lateralis 
muscle (described above). A blood pressure cuff was placed at the most proximal portion of 
the thigh and inflated to 200-220 mmHg to cause arterial occlusion. This cuff pressure was 
maintained for five minutes. The pressure in the cuff was then released and the cuff was 
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removed. The NIRS device recorded data for five minutes prior to cuff inflation, during the 
five minutes while the cuff was inflated, and for five minutes after cuff deflation. All 
subsequent NIRS data during the leg extension exercises were expressed as a percentage of 
the difference between the minimal tissue oxygenation during ischemia and maximal 
oxygenation following recovery from ischemia that occurs during the PORH procedure (24).  
Statistical Analyses 
 
Means ± standard errors for descriptive assessments are reported in Table 1. 
Independent sample’s t-tests were used to compare the means of the all descriptive 
assessments between sarcopenic and non-sarcopenic groups. Three separate two-way mixed 
factorial analyses of variance (ANOVA) with a 2 × 2 model and repeated measures on the 
Site factor (site [EMG vs. NIRS] × group [sarcopenic vs. non-sarcopenic]) were used to 
compare the means for vastus lateralis muscle thickness, subcutaneous fat thickness, and 
echo intensity. Nine separate three-way mixed factorial analyses of variance (ANOVAs) with 
a 5 × 2 × 2 model and repeated measures on the Repetitions and Task factors (Repetitions [1 
vs. 2 vs. 3 vs. 4 vs. 5] × task [5-RM vs. fatigue] × group [sarcopenic vs. non-sarcopenic]) 
were used to compare the means for absolute EMGRMS (μV), normalized EMGRMS 
(%MAX), absolute EMGMPF (Hz), normalized EMGMPF (%MAX), HHb (%PORH), O2Hb 
(%PORH), THb (%PORH), HBDiff (%PORH), and TSI (%). Significant interactions, main 
effects of the marginal means, or simple main effects were followed up with lower-order 
ANOVAs, paired t-tests for repeated measures factors, and independent t-tests for between-
subjects factors and Fisher’s Least Significant Difference adjustments for multiple 
comparisons. Partial h2 effect sizes and Cohen’s d effect sizes (d) were calculated and 
reported for all F- and t-ratios, respectively (13). All statistical analyses were performed using 
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IBM SPSS for Macintosh, Version 24 (IBM Corp., Chicago, IL, USA). An alpha of p ≤ 0.05 
was considered statistically significant for all comparisons.  
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CHAPTER IV 
RESULTS 
Descriptive Assessments  
Demographics. There were no significant differences (p > 0.05) in age (d = 0.18), 
height (d = 0.30), or weight (d = 1.35) between the means of the sarcopenic and non-
sarcopenic groups (Table 1). However, BMI was lower in the non-sarcopenic group (p = 
0.03). 
Body Composition. There were no significant differences (p > 0.05) in fat-free 
mass (d = 0.42) between the means of the sarcopenic and non-sarcopenic groups (Table 
1). The sarcopenic group exhibited greater mean fat mass (p = 0.003, d = 2.41) and 
percent body fat (p = 0.007, d = 2.16) than the non-sarcopenic group, while mean RSMI 
was significantly greater (p = 0.001, d = 4.259) in the non-sarcopenic than the sarcopenic 
group. 
Muscle Size. There were no site × group interactions for vastus lateralis muscle 
thickness (p = 0.313, h2 = 0.113), subcutaneous adipose tissue thickness (p = 0.652, h2 = 
0.024), or echo intensity (p = 0.485, h2 = 0.056). There were no main effects for site (p = 
0.472, h2 = 0.059) or group (p = 0.626, h2 = 0.027) for vastus lateralis muscle thickness. 
However, there were main effects for site for subcutaneous fat thickness (p = 0.002, h2 = 
0.687) and echo intensity (p = 0.007, h2 = 0.577) and main effects for group for 
subcutaneous fat thickness (p = 0.047, h2 =  0.369) and echo intensity (p = 0.039, h2 = 
0.392). Subcutaneous adipose tissue thickness was greater and echo intensity was lower (p = 
0.015, d = 1.21; p = 0.004, d = 1.64) at the EMG site than the NIRS site for the non-
sarcopenic group only. Subcutaneous adipose tissue thickness (p = 0.026, d = 1.56) and echo 
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intensity (p = 0.027, d = 1.63) were greater in the sarcopenic group than the non-sarcopenic 
group at the NIRS site only.  
Muscle Strength, Endurance, and Functionality. There were no significant 
differences (p > 0.05) in mean absolute 5-RM leg extension strength (d = 0.88) or mean 
gait speed (d = 1.00) between the sarcopenic and non-sarcopenic groups (Table 1). 
However, the sarcopenic group exhibited significantly lower (p = 0.008, d = 2.13) mean 
handgrip strength than the non-sarcopenic group (Table 1).  
Surface Electromyography  
 There were no repetition × task × group interactions for absolute EMGRMS (p = 
0.142, h2 = 0.170), normalized EMGRMS (p = 0.091, h2 = 0.195), absolute EMGMPF (p = 
0.845, h2 = 0.037), or normalized EMGMPF (p = 0.611, h2 = 0.070). There were no 
repetition × task interactions for absolute EMGRMS (p = 0.726, h2 = 0.054), normalized 
EMGRMS (p = 0.482, h2 = 0.085), absolute EMGMPF (p = 0.374, h2 = 0.108), or normalized 
EMGMPF (p = 0.171, h2 = 0.168). There were no repetition × group interactions for 
absolute EMGRMS (p = 0.997, h2 = 0.004), normalized EMGRMS (p = 0.482, h2 = 0.085), 
absolute EMGMPF (p = 0.675, h2 = 0.061), or normalized EMGMPF (p = 0.171, h2 = 0.168). 
There were no task × group interactions for absolute EMGRMS (p = 0.781, h2 = 0.009) or 
normalized EMGRMS (p = 0.657, h2 = 0.023); however, there task × group interactions for 
absolute EMGMPF (p = 0.008, h2 = 0.560) and normalized EMGMPF (p = 0.040, h2 = 
0.390). The marginal means for absolute EMGMPF (p = 0.017, d = 0.973) and normalized 
EMGMPF (p = 0.039, d = 1.98) (collapsed across repetition) were greater during the 5-RM 
than the fatiguing task for the non-sarcopenic group (sarcopenic group; p = 0.229, d = 
0.895 [normalized EMGMPF], p = 0.167, d = 0.648 [raw EMGMPF])(Figure 2). The 
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marginal means for both absolute and normalized EMGMPF (collapsed across repetition) 
were not different between groups during the 5-RM (p = 0.075 – 0.638, d = 0.224 - 1.17) 
or fatiguing task (p = 0.530 – 0.937, d = 0.047 - 0.402).  
There were significant main effects for repetition for absolute EMGRMS (p = 
0.001, h2 = 0.534), normalized EMGRMS (p = 0.001, h2 = 0.600), absolute EMGMPF (p = 
0.001, h2 = 0.434), and normalized EMGMPF (p = 0.001, h2 = 0.478). Post-hoc 
comparisons indicated that the marginal means (collapsed across task and group) for 
absolute EMGRMS during repetitions 3 (p = 0.002, d = 0.673), 4 (p = 0.001, d = 0.688), 
and 5 (p = 0.001, d = 0.773) were greater than repetition 1, but there were no other 
differences among repetitions (p = 0.060 – 0.701, d = 0.029 – 0.420) (Figure 4). The 
marginal means (collapsed across task and group) for normalized EMGRMS during 
repetitions 2 (p = 0.025, d = 0.884), 3 (p = 0.001, d = 1.373), 4 (p = 0.001, d = 1.409), 
and 5 (p = 0.001, d = 1.754) were greater than repetition 1, and repetition 5 was greater 
than repetition 2 (p = 0.039, d = 0.581); however, no other repetitions were different (p = 
0.059 – 0.877, d = 0.025 – 0.403) (Figure 4). The marginal means (collapsed across task 
and group) for absolute EMGMPF during repetitions 4 (p = 0.009 – 0.041, d = 0.287 – 
0.579) and 5 (p = 0.004 – 0.014, d = 0.309 – 0.590) were lower than repetition 1, 2, and 
3, but there were no other differences among repetitions (p = 0.093 – 0.721, d = 0.037 – 
0.299) (Figure 5). The marginal means (collapsed across task and group) for normalized 
EMGMPF during repetitions 4 (p = 0.004 – 0.010, d = 0.358 - 0.471) and 5 (p = 0.007 – 
0.009, d = 0.434 – 0.555) were lower than repetitions 1 and 2, repetition 3 was also lower 
than repetition 5 (p = 0.013, d = 0.295), but there were no other differences among 
repetitions (p = 0.063 – 0.720, d = 0.067 – 0.236) (Figure 5). There were no main effects 
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for task for absolute EMGRMS (p = 0.778, h2 = 0.009) or normalized EMGRMS (p = 0.847, 
h2 = 0.004), and there were no main effects for group for absolute EMGRMS (p = 0.331, h2 
= 0.105) or normalized EMGRMS (p = 0.704, h2 = 0.017).  
Near-infrared Spectroscopy 
 There were no repetition × task × group interactions for HHb (p = 0.765, h2  = 
0.016), O2Hb (p = 0.485, h2 = 0.073), THb (p = 0.194, h2  = 0.163), HBDiff (p = 0.780, h2  
= 0.019), or TSI (p = 0.735, h2 = 0.022). There were no repetition × task interactions for 
HHb (p = 0.634, h2  = 0.034), O2Hb (p = 0.431, h2  = 0.086), THb (p = 0.489, h2  = 0.80), 
HBDiff (p = 0.412, h2 = 0.088) , or TSI (p = 0.466, h2  = 0.071). There were no task × 
group interactions for HHb (p = 0.282, h2  = 0.127), O2Hb (p = 0.091, h2  = 0.285), THb (p 
= 0.085, h2  = 0.294), HBDiff (p = 0.991, h2  = 0.001), or TSI (p = 0.550, h2  = 0.041). 
There were no repetition × group interactions for THb (p = 0.467, h2  = 0.063) or HBDiff 
(p = 0.321, h2  = 0.117); however, there were repetition × group interactions for O2Hb (p 
= 0.046, h2  = 0.230), HHb (p = 0.020, h2  = 0.270) and TSI (p = 0.045, h2 = 0.231).  
For the marginal means in the non-sarcopenic group (collapsed across task) there 
were main effects for repetition for HHb (p = 0.001, h2 = 0.769) and TSI (0.001, h2 = 0.754), 
but not for O2Hb (p = 0.167, h2 = 0.265). Post-hoc comparisons indicated that the 
marginal means for HHb during repetitions 2 (p = 0.007, d = 0.687), 3 (p = 0.010, d = 
1.285), 4 (p = 0.006, d = 1.637), and 5 (p = 0.006, d = 1.598) were greater than repetition 
1. HHb during repetitions 3 (p = 0.041, d = 0.596), 4 (p = 0.017, d = 0.905), and 5 (p = 
0.019, d = 0.886) were greater than repetition 2. HHb during repetitions 4 (p = 0.007, d = 
0.277) and 5 (p = 0.004, d = 0.275) were greater than repetition 3; however, HHb during 
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repetition 5 (p = 0.928, d = 0.004) was not greater than repetition 4. TSI during 
repetitions 2 (p = 0.043, d = 0.615), 3 (p = 0.017, d = 1.180), 4 (p = 0.009, d = 1.394) and 
5 (p = 0.008, d = 1.383) were less than repetition 1. TSI during repetitions 3 (p = 0.012, d 
= 0.629), 4 (p = 0.003, d = 0.857), and 5 (p = 0.006, d = 0.853) were less than repetition 
2. TSI during repetition 4 (p = 0.001, d = 0.212) was less than repetition 3, but TSI during 
repetition 3 (p = 0.076, d = 0.193) and 4 (p = 0.803, d = 0.021) were not different from 
repetition 5 (Figure 6).  
For the marginal means in the sarcopenic group (collapsed across task) there were 
main effects for repetition for HHb (p = 0.008, h2 = 0.559), O2Hb (p = 0.021, h2 = 0.496), 
and TSI (p = 0.002, h2 = 0.629). However, post-hoc comparisons indicated no differences 
in HHb (p = 0.066 – 0.273, d = 0.121 – 0.836) or O2Hb (p = 0.077 – 0.758, d = 0.037 – 
0.530) among any repetitions. TSI during repetitions 3 (p = 0.049, d = 0.348) and 5 (p = 
0.047, d = 0.582) were different than repetition 1, TSI during repetitions 4 (p = 0.018, d = 
0.438) and 5 (p = 0.023, d = 0.534) were different than repetition 2, but no other 
repetitions were different (p = 0.070 – 0.488, d = 0.074 – 0.492) (Figure 6).  
For all 5 repetitions, the marginal mean for TSI (collapsed across task) was lower 
in the sarcopenic group than the non-sarcopenic group (p = 0.005 – 0.014, d = 1.861 – 
2.258). There were no differences between groups for HHb (p = 0.207 – 0.718, d = 0.231 
– 1.017) or O2Hb (p = 0.300 – 0.847, d = 0.118 – 0.406) for any repetitions (Figure 6).  
There were no main effects for task for HHb (p = 0.288, h2  = 0.124), O2Hb (p 
=0.307, h2  = 0.115), THb (p = 0.577, h2  = 0.036), HBDiff (p = 0.240, h2  = 0.150), or TSI 
(p = 0.508, h2  = 0.050). There were no main effects for group for THb (p = 0.449, h2 = 
0.065) or HBDiff (p = 0.357, h2 = 0.095). There was a significant main effect for 
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repetition for HBDiff (p = 0.001, h2 = 0.670), but not for THb (p = 0.066, h2 = 0.212). 
Post-hoc comparisons indicated that the marginal means for HBDiff (collapsed across 
task and group) during repetitions 2 (p = 0.015, d = 0.394), 3 (p = 0.001, d = 0.958), 4 (p 
= 0.001, d = 0.93) and 5 (p = 0.001, d = 1.135) were less than repetition 1. Additionally, 
HBDiff during repetitions 3 (p = 0.003, d = 0.509), 4 (p = 0.002, d = 0.620), and 5 (p = 
0.004, d = 0.702) were less than repetition 2. There were no other differences among 
repetitions (p = 0.059 – 0.150, d = 0.079 – 0.219) (Figure 7).  
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CHAPTER V 
DISCUSSION 
 This was the first study to compare muscle strength, size, activation, and tissue 
oxygenation between older women with and without sarcopenia during dynamic fatiguing 
tasks. Despite no differences in leg extensor muscle size or strength between sarcopenic 
versus non-sarcopenic older women, the sarcopenic older women exhibited 13 – 21% 
lower TSI scores across all repetitions of the 5-RM and 30% 1-RM fatiguing tasks. 
Although EMGRMS increased, while EMGMPF decreased from repetitions 1 to 5 during 
both the 5-RM and 30% 1-RM loads, there were no differences between the sarcopenic 
versus non-sarcopenic groups. 
 Based on handgrip strength and RSMI cutoffs, the sarcopenic group met the 
existing qualifications (15). Despite meeting the sarcopenic qualifications, the sarcopenic 
and non-sarcopenic groups did not differ in age, height, weight, gait speed, fat-free mass, 
leg extensor muscle cross sectional area, or vastus lateralis muscle thickness, nor were 
there differences in leg extension strength or endurance. There were, however, greater 
body fat indicators in the sarcopenic group by fat mass, percent body fat, subcutaneous 
fat thickness, and echo intensity (Table 1). These findings suggested that the sarcopenic 
group was also more obese than the non-sarcopenic group. Sarcopenic obesity has been 
studied and may adversely impact the health and function of older adults (4,6,28). The 
results of the present study indicate that body fat was present at a greater degree in nearly 
all measured locations, such as overall fat mass, percent body fat, site-specific 
subcutaneous fat thickness, and possibly infiltrated within the muscle via echo intensity. 
Even sample body mass index (BMI) calculations showed that only 2 out of 6 non-
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sarcopenic older women were greater than 25 kg•m-1, while the remaining 4 were 22 – 24 
kg•m-1. In contrast, 4 out of 5 sarcopenic women were greater than 25 kg•m-1, with 1 
greater than 30 kg•m-1. Interestingly, a previous study, Ohara et al. (57) found that pulse 
wave velocity, which is a reflection of arterial stiffness, was higher in older individuals 
with sarcopenic-obesity than individuals classified as only sarcopenic and only obese. 
This suggests that blood flow may be impaired to a greater degree in sarcopenic-obese 
individuals than sarcopenia or obesity alone.  
 Another interesting finding in the present study was the lack of differences in leg 
extensor strength or muscle size between the sarcopenic and non-sarcopenic women. The 
fact that upper-body handgrip strength was lower in the sarcopenic group, while lower-
body leg extension strength was not different, suggests that upper-body, non-weight 
bearing muscles may deteriorate in strength quicker than lower-body, weight-bearing 
muscles in older women. It is well accepted that age-related declines in muscular 
performance are muscle-specific and depend on the amount and intensity of physical 
activity performed across a life span (39). Since the subjects recruited for this study self-
reported no involvement in resistance training, it may be reasonable to assume the daily 
physical activity these individuals perform may be predominately using weight-bearing 
muscles. Therefore, the presence of sarcopenia may be most evident in non-weight-
bearing muscles, such as the finger flexors during handgrip strength, but less evident in 
weight-bearing muscles, such as the leg extensors during leg extension strength.  
 A consequence of the research design of the present study was a distinguished 
clinical classification of sarcopenic based on handgrip strength and RSMI. However, 
subjects ended up being matched for leg extension strength, endurance, and muscle size. 
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Therefore, when comparing the fatiguing leg extension tasks at 5-RM and 30% of 
estimated 1-RM, the only measured descriptive physiological difference between 
sarcopenia and non-sarcopenia groups was subcutaneous fat and echo intensity. Previous 
studies have hypothesized that subcutaneous fat can dampen the EMG signal (59,60) and 
the NIRS signal (55). However, it should be noted that subcutaneous fat and echo 
intensity were not different between sarcopenic and non-sarcopenic at the EMG electrode 
site. Subcutaneous fat and echo intensity were greater in the sarcopenic group at the 
NIRS site only (Table 1). Thus, it may be reasonable to consider body fat as a 
confounding factor for NIRS, but not for EMG time or frequency domain variables. The 
range of adipose tissue thickness was 0.61 – 1.064 cm for the non-sarcopenic group and 
0.83 – 1.754 cm for the sarcopenic group. The Portamon NIRS device has a range of 
2cm, therefore, we can reasonably assume that the NIRS device was able to detect the 
muscle underlying the subcutaneous adipose tissue for all of our subjects. Even yet, 
adipose tissue reflects light to a greater degree than muscle tissue. Therefore, the 
presence of subcutaneous and intramuscular adipose tissue may increase the scattering of 
light, which artificially decreases the amount of light detected at the light source, thus 
decreasing or dampening the signal. This highlights the need of normalization methods 
such as the PORH protocol when comparing group mean values of the NIRS variables. 
By expressing the NIRS values to each individual’s range, it may be possible to account 
for the heterogeneity in the underlying tissue, whether it was varying thicknesses of 
subcutaneous adipose tissue or varying concentrations of infiltrated intramuscular 
adipose tissue (3,45).   
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 Previous studies have shown greater variability in muscle activation in older 
versus younger adults (64). Previous studies have also shown that older adults tend to 
demonstrate less muscle fatiguability than younger adults (34). Collectively, these 
previous findings may explain why neither EMG amplitude nor EMG frequency were 
different between sarcopenic and non-sarcopenic groups for either the 5-RM or 30% 1-
RM fatiguing tasks. If greater variability is expected among muscle activation strategies 
of older adults in general, finding differences in EMG between sarcopenic and non-
sarcopenic women without differences in leg extension strength, endurance, or muscle 
size may be difficult.  
 The patterns of responses in EMG amplitude and frequency in the present study 
followed the same characteristics of high- versus low-load fatigue in younger adults (38). 
Jenkins et al (38) showed during high load and low load leg extension exercises to failure 
in college-aged men and women, EMGAMP increased and EMGMPF will decreased across 
repetitions. Thus, the present study supported the conclusions of previous authors (35) 
that neuromuscular control strategies during fatigue are similar between young versus 
older adults.  
 Another interesting finding of the present study was that despite no differences in 
muscle size, strength, or endurance, significant differences in TSI during the 5-RM and 
30% 1-RM fatiguing tasks between the sarcopenic and non-sarcopenic did still exist. 
Therefore, oxygen supply was not able to keep up with oxygen utilization as much in the 
sarcopenic group than the non-sarcopenic group. This is similar to findings of a previous 
studies showing impaired oxygen kinetics in mobility-impaired individuals (49) and 
adults with chronic obstructive pulmonary disease (58) compared to healthy individuals. 
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Thus, the present study supports previous conclusions suggesting that one mechanism 
contributing to sarcopenia may involve the nutritive flow hypothesis or the inability to 
deliver nutrients and oxygen to working skeletal muscles (14).  
The patterns of responses in NIRS variables in the present study followed the 
same characteristics of previous studies examining dynamic fatiguing exercises (11,51). 
As the oxygen demand increases for the working muscles, O2HB and HHB will exhibit 
an inverse relationship where O2Hb decreases and HHB increases during the fatiguing 
task as oxygen is consumed by the muscle. Furthermore, tissue saturation index (TSI) 
represents the balance between oxygen supply to the muscle and oxygen utilization in the 
muscle and is expected to decrease during fatiguing tasks as oxygen utilization exceeds 
oxygen supply. Changes in total hemoglobin (tHB) represents changes in blood volume 
and is expected to increase with fatiguing exercise due to the increase in oxygen demand 
(50). HBDiff is not commonly reported in previous studies, however, recent 
recommendations (3) have emphasized the need to report all available NIRS variables. 
HBDiff represents the difference between O2Hb and HHb and may serve as additional 
variable describing the balance between oxygen supply and utilization.  
 It is hypothesized that (a) oxygenated hemoglobin will decrease while 
deoxygenated hemoglobin and total hemoglobin will increase during the fatiguing task 
and 5-RM, (b) EMGAMP will increase and EMGMPF will decrease during the fatiguing 
task and 5-RM, and (c) patterns of response during the fatiguing task will vary between 
sarcopenia status.  
This cross-sectional, exploratory pilot study identified differences in RSMI, 
handgrip strength, and vastus lateralis muscle tissue oxygenation, despite no differences 
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in leg extensor size, strength, or endurance. Even though clinical classifications exist for 
sarcopenia, age-related losses in muscle mass, strength, and function may not impact all 
muscles uniformly. The findings of our previous study support the hypothesis that 
EMGAMP increased and EMGMPF decreased during the fatiguing task. However, if greater 
variability is expected among muscle activation strategies of older adults (64), using 
EMG to monitor differences between sarcopenic and non-sarcopenic women without 
differences in leg extensor size, strength, and endurance may be difficult. Future studies 
are needed to further explore the findings in the present study that muscle tissue 
oxygenation, and possibly skeletal muscle blood flow, is lower in sarcopenic than non-
sarcopenic older women. This study supported the hypothesis that deoxygenated 
hemoglobin will increase during the 5-RM and fatiguing tasks in the non-sarcopenic 
group only. Interestingly, deoxygenated hemoglobin did not increase in the sarcopenic 
group. Additionally, oxygenated hemoglobin did not decrease during the 5-RM and 
fatiguing tasks for either group. However, there were differences in tissue saturation 
index during the 5-RM and fatiguing tasks. NIRS measurements may be important to 
consider when recommending exercise or nutrition interventions for either oxygen or 
dietary nutrient delivery to working skeletal muscles. (18) 
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Table 1. Means (± standard error) for descriptive outcome measures in non-
sarcopenic and sarcopenic women.  
  
Non-sarcopenic 
(n = 6) 
Sarcopenic  
(n = 5) 
Age (y) 75.8 ± 2.6 74.5 ± 3.1 
Height (cm) 160.2 ± 2.9 157.8 ± 3.8 
Weight (kg) 62.2 ± 2.9 71.5 ± 3.0 
Fat Mass (kg) 22.7 ± 1.1* 29.1 ± 1.2 
Lean Mass (kg) 41.0 ± 3.7 38.2 ± 1.5 
Percent Body Fat (%) 36.7 ± 1.2* 41.8 ± 0.7 
Relative Skeletal Muscle Index (%) 29.3 ± 0.9* 25.9 ± 0.7 
Leg Extensor Muscle Cross-sectional Area (cm2) 30.5 ± 1.6 31.6 ± 1.1 
Vastus Lateralis Muscle ThicknessNIRS(cm) 1.90 ± 0.08 2.03 ± 0.11 
Vastus Lateralis Subcutaneous Fat ThicknessNIRS (cm) 0.89 ± 0.08*‡ 1.34 ± 0.16 
Vastus Lateralis Echo IntensityNIRS (a.u.) 105.8 ± 3.2*‡ 116.5 ± 2.2 
Vastus Lateralis Muscle ThicknessEMG(cm) 1.93 ± 0.07 1.87 ± 0.05 
Vastus Lateralis Subcutaneous Fat ThicknessEMG (cm) 1.25 ± 0.15 1.63 ± 0.16 
Vastus Lateralis Echo IntensityEMG (a.u.) 89.2 ± 4.9 105.6 ± 7.7 
Absolute leg extension strength (kg)† 9.5 ± 1.1 7.4 ± 0.9 
Repetitions Completed at 30% Est. 1-RM 13.2 ± 1.2 13.6 ± 3.0 
Handgrip Strength (kg) 25.1 ± 2.1* 16.5 ±1.1 
Gait Speed (m•s-1) 1.10 ± 0.06 0.93 ± 0.07 
* Indicates significant difference between non-sarcopenic and sarcopenic subjects (p 
≤ 0.05) 
‡ Indicates significant difference from EMG site (p ≤ 0.05)  
†Mass lifted during the 5RM task (kg)   
   
 
Table (2). Means (± standard error) for EMG time and frequency 
domains for the first repetition of the 5RM.  
  
Non-sarcopenic 
(n = 6) 
Sarcopenic  
(n = 5) 
EMG Amplitude (μVRMS) 92.5 ± 13.5 71.5 ± 9.1 
EMG Frequency (HzMPF) 72.1 ± 4.7 52.1 ± 8.5 
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Figure (1). Torque (Nm) across the 5RM (left) and fatiguing (right) leg extension 
repetitions for all participants. Gray lines indicate sarcopenic and black lines indicate 
non-sarcopenic.  
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Figure (2). Absolute and normalized EMG variables across the 5RM (left) and fatiguing 
leg extensions (right). Black lines indicate non-sarcopenic and gray lines indicate 
sarcopenic.  
*Indicates EMG MPF collapsed across repetition was greater during the 5RM 
than fatiguing task for the non-sarcopenic group only (p ≤ 0.05).   
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Figure (3). NIRS variables across the 5RM and fatiguing leg extensions. Black lines 
indicate non-sarcopenic and gray lines indicate sarcopenic.  
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Figure (4). Absolute EMGRMS (top) and normalized EMGRMS (Bottom) collapsed across 
group and task.  
*Indicates significantly greater than repetition 1.   
†Indicates significantly greater than repetition 2.  
 
 
 
 
 
 
0
0 1 2 3 4 5 6
60
70
80
90
100
110
120
130
EM
G R
M
S
(μ
V)
* * * 
0
0 1 2 3 4 5 6
Raw EMG RMS
60
70
80
90
100
110
120
130
140
150
EM
G R
M
S
(%
m
ax
)
* * * *, † 
 63  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (5). Absolute EMGMPF (Top) and normalized EMGMPF (bottom) collapsed across 
group and task.  
*Indicates significantly less than repetition 1.  
† Indicates significantly less than repetition 2.  
‡ Indicates significantly less than repetition 3.  
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Figure (6). HHb (Top), O2Hb (Middle), and TSI (Bottom) collapsed across task in the non-
sarcopenic (black) and sarcopenic (gray).  
* Indicates significantly different than repetition 1.  
† Indicates significantly different than repetition 2.  
‡ Indicates significantly different than repetition 3.  
§ Indicates significant difference between groups.  
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Figure (7). HBDiff collapsed across group and task.  
*Indicates significantly different than repetition 1.  
†Indicates significantly different than repetition 2.  
  
0
10
20
30
40
50
60
70
0 1 2 3 4 5 6
HB
Di
ff 
(%
PO
RH
)
HBDIFF
*, † *, † *, † 
* 
 66  
REFERENCES 
1.  Ahtiainen, JP, Hoffren, M, Hulmi, JJ, Pietikäinen, M, Mero, AA, Avela, J, et al. 
Panoramic ultrasonography is a valid method to measure changes in skeletal 
muscle cross-sectional area. Eur J Appl Physiol 108: 273–279, 2010. 
2.  American Society of Hand Therapists. Clinical assessment recommendations. 
Chicago (401 N. Michigan Ave., Chicago IL 60611-4267): The Society, 1992. 
3.  Barstow, TJ. Understanding near infrared spectroscopy and its application to 
skeletal muscle research. J Appl Physiol Bethesda Md 1985 126: 1360–1376, 2019. 
4.  Batsis, JA and Villareal, DT. Sarcopenic obesity in older adults: aetiology, 
epidemiology and treatment strategies. Nat Rev Endocrinol 14: 513, 2018. 
5.  Baumgartner, RN, Koehler, KM, Gallagher, D, Romero, L, Heymsfield, SB, Ross, RR, 
et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J 
Epidemiol 147: 755–763, 1998. 
6.  Baumgartner, RN, Wayne, SJ, Waters, DL, Janssen, I, Gallagher, D, and Morley, JE. 
Sarcopenic Obesity Predicts Instrumental Activities of Daily Living Disability in the 
Elderly. Obes Res 12: 1995–2004, 2004. 
7.  Bergman, BC and Brooks, GA. Respiratory gas-exchange ratios during graded 
exercise in fed and fasted trained and untrained men. J Appl Physiol 86: 479–487, 
1999. 
8.  Bonadonna, RC, Groop, LC, Simonson, DC, and DeFronzo, RA. Free fatty acid and 
glucose metabolism in human aging: evidence for operation of the Randle cycle. 
Am J Physiol-Endocrinol Metab 266: E501–E509, 1994. 
9.  Buford, TW, Anton, SD, Judge, AR, Marzetti, E, Wohlgemuth, SE, Carter, CS, et al. 
Models of Accelerated Sarcopenia: Critical Pieces for Solving the Puzzle of Age-
Related Muscle Atrophy. Ageing Res Rev 9: 369–383, 2010. 
10.  Castillo, EM, Goodman-Gruen, D, Kritz-Silverstein, D, Morton, DJ, Wingard, DL, and 
Barrett-Connor, E. Sarcopenia in elderly men and women: the Rancho Bernardo 
study. Am J Prev Med 25: 226–231, 2003. 
11.  Chin, LMK, Kowalchuk, JM, Barstow, TJ, Kondo, N, Amano, T, Shiojiri, T, et al. The 
relationship between muscle deoxygenation and activation in different muscles of 
the quadriceps during cycle ramp exercise. J Appl Physiol Bethesda Md 1985 111: 
1259–1265, 2011. 
 67  
12.  Clark, BC, Collier, SR, Manini, TM, and Ploutz-Snyder, LL. Sex differences in muscle 
fatigability and activation patterns of the human quadriceps femoris. Eur J Appl 
Physiol 94: 196–206, 2005. 
13.  Cohen. Statistical Power Analysis for the Behavioral Sciences - 1st Edition. New 
York, New York: Routledge Academic, 1988 [cited 2018 Feb 12].Available from: 
https://www.elsevier.com/books/statistical-power-analysis-for-the-behavioral-
sciences/cohen/978-0-12-179060-8 
14.  Cramer, JT, Cruz-Jentoft, AJ, Landi, F, Hickson, M, Zamboni, M, Pereira, SL, et al. 
Impacts of High-Protein Oral Nutritional Supplements Among Malnourished Men 
and Women with Sarcopenia: A Multicenter, Randomized, Double-Blinded, 
Controlled Trial. J Am Med Dir Assoc 17: 1044–1055, 2016. 
15.  Cruz-Jentoft, AJ, Baeyens, JP, Bauer, JM, Boirie, Y, Cederholm, T, Landi, F, et al. 
Sarcopenia: European consensus on definition and diagnosis. Age Ageing 39: 412–
423, 2010. 
16.  Dickinson, KM, Keogh, JB, and Clifton, PM. Effects of a low-salt diet on flow-
mediated dilatation in humans. Am J Clin Nutr 89: 485–490, 2009. 
17.  Dinenno, FA, Jones, PP, Seals, DR, and Tanaka, H. Limb blood flow and vascular 
conductance are reduced with age in healthy humans: relation to elevations in 
sympathetic nerve activity and declines in oxygen demand. Circulation 100: 164–
170, 1999. 
18.  Donato, AJ, Uberoi, A, Wray, DW, Nishiyama, S, Lawrenson, L, and Richardson, RS. 
Differential effects of aging on limb blood flow in humans. Am J Physiol-Heart Circ 
Physiol 290: H272–H278, 2006. 
19.  Eskurza, I, Myerburgh, LA, Kahn, ZD, and Seals, DR. Tetrahydrobiopterin augments 
endothelium-dependent dilatation in sedentary but not in habitually exercising 
older adults. J Physiol 568: 1057–1065, 2005. 
20.  Fujita, S, Dreyer, HC, Drummond, MJ, Glynn, EL, Cadenas, JG, Yoshizawa, F, et al. 
Nutrient signalling in the regulation of human muscle protein synthesis. J Physiol 
582: 813–823, 2007. 
21.  Fujita, S, Glynn, EL, Timmerman, KL, Rasmussen, BB, and Volpi, E. 
Supraphysiological hyperinsulinemia is necessary to stimulate skeletal muscle 
protein anabolism in older adults: Evidence of a true age-related insulin resistance 
of muscle protein metabolism. Diabetologia 52: 1889–1898, 2009. 
22.  Goedecke, JH, Gibson, ASC, Grobler, L, Collins, M, Noakes, TD, and Lambert, EV. 
Determinants of the variability in respiratory exchange ratio at rest and during 
 68  
exercise in trained athletes. Am J Physiol-Endocrinol Metab 279: E1325–E1334, 
2000. 
23.  Goodpaster, BH and Sparks, LM. Metabolic flexibility in health and disease. Cell 
Metab 25: 1027–1036, 2017. 
24.  Grassi, B, Pogliaghi, S, Rampichini, S, Quaresima, V, Ferrari, M, Marconi, C, et al. 
Muscle oxygenation and pulmonary gas exchange kinetics during cycling exercise 
on-transitions in humans. J Appl Physiol 95: 149–158, 2003. 
25.  Hermens, HJ, Freriks, B, Merletti, R, Stegeman, D, Blok, J, Rau, G, et al. European 
Recommendations for Surface ElectroMyoGraphy. 4 
26.  Hida, T, Shimokata, H, Sakai, Y, Ito, S, Matsui, Y, Takemura, M, et al. Sarcopenia and 
sarcopenic leg as potential risk factors for acute osteoporotic vertebral fracture 
among older women. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur 
Sect Cerv Spine Res Soc 25: 3424–3431, 2016. 
27.  Hirani, V, Blyth, F, Naganathan, V, Le Couteur, DG, Seibel, MJ, Waite, LM, et al. 
Sarcopenia Is Associated With Incident Disability, Institutionalization, and Mortality 
in Community-Dwelling Older Men: The Concord Health and Ageing in Men Project. 
J Am Med Dir Assoc 16: 607–613, 2015. 
28.  Hirani, V, Naganathan, V, Blyth, F, Le Couteur, DG, Seibel, MJ, Waite, LM, et al. 
Longitudinal associations between body composition, sarcopenic obesity and 
outcomes of frailty, disability, institutionalisation and mortality in community-
dwelling older men: The Concord Health and Ageing in Men Project. Age Ageing 
46: 413–420, 2017. 
29.  Hong, Y and Bartlett, R. Routledge Handbook of Biomechanics and Human 
Movement Science. Routledge, 2008. 
30.  Hunter, SK. Sex Differences and Mechanisms of Task-Specific Muscle Fatigue. Exerc 
Sport Sci Rev 37: 113–122, 2009. 
31.  Hunter, SK. Sex differences in human fatigability: mechanisms and insight to 
physiological responses. Acta Physiol Oxf Engl 210: 768–789, 2014. 
32.  Hunter, SK. The Relevance of Sex Differences in Performance Fatigability. Med Sci 
Sports Exerc 48: 2247–2256, 2016. 
33.  Hunter, SK. Sex differences in fatigability of dynamic contractions. Exp Physiol 101: 
250–255, 2016. 
 69  
34.  Hunter, SK, Critchlow, A, and Enoka, RM. Muscle endurance is greater for old men 
compared with strength-matched young men. J Appl Physiol Bethesda Md 1985 99: 
890–897, 2005. 
35.  Hunter, SK, Pereira, HM, and Keenan, KG. The aging neuromuscular system and 
motor performance. J Appl Physiol 121: 982–995, 2016. 
36.  Iannuzzi-Sucich, M, Prestwood, KM, and Kenny, AM. Prevalence of sarcopenia and 
predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A 
Biol Sci Med Sci 57: M772-777, 2002. 
37.  Janssen, I, Heymsfield, SB, and Ross, R. Low relative skeletal muscle mass 
(sarcopenia) in older persons is associated with functional impairment and physical 
disability. J Am Geriatr Soc 50: 889–896, 2002. 
38.  Jenkins, NDM, Housh, TJ, Bergstrom, HC, Cochrane, KC, Hill, EC, Smith, CM, et al. 
Muscle activation during three sets to failure at 80 vs. 30 % 1RM resistance 
exercise. Eur J Appl Physiol 115: 2335–2347, 2015. 
39.  Jenkins, NDM, Miller, JM, Buckner, SL, Cochrane, KC, Bergstrom, HC, Hill, EC, et al. 
Test–Retest Reliability of Single Transverse versus Panoramic Ultrasound Imaging 
for Muscle Size and Echo Intensity of the Biceps Brachii. Ultrasound Med Biol 41: 
1584–1591, 2015. 
40.  Jenkins, NDM, Miramonti, AA, Hill, EC, Smith, CM, Cochrane-Snyman, KC, Housh, 
TJ, et al. Greater Neural Adaptations following High- vs. Low-Load Resistance 
Training. Front Physiol 8, 2017.Available from: 
https://www.frontiersin.org/articles/10.3389/fphys.2017.00331/full 
41.  Katsanos, CS, Kobayashi, H, Sheffield-Moore, M, Aarsland, A, and Wolfe, RR. Aging 
is associated with diminished accretion of muscle proteins after the ingestion of a 
small bolus of essential amino acids. Am J Clin Nutr 82: 1065–1073, 2005. 
42.  Katsanos, CS, Kobayashi, H, Sheffield-Moore, M, Aarsland, A, and Wolfe, RR. A high 
proportion of leucine is required for optimal stimulation of the rate of muscle 
protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol 
Metab 291: E381-387, 2006. 
43.  Kemps, HMC, Prompers, JJ, Wessels, B, De Vries, WR, Zonderland, ML, Thijssen, 
EJM, et al. Skeletal muscle metabolic recovery following submaximal exercise in 
chronic heart failure is limited more by O 2 delivery than O 2 utilization. Clin Sci 118: 
203–210, 2009. 
44.  Kim, J, Wang, Z, Heymsfield, SB, Baumgartner, RN, and Gallagher, D. Total-body 
skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry 
method. Am J Clin Nutr 76: 378–383, 2002. 
 70  
45.  Koga, S, Poole, DC, Fukuoka, Y, Ferreira, LF, Kondo, N, Ohmae, E, et al. 
Methodological validation of the dynamic heterogeneity of muscle deoxygenation 
within the quadriceps during cycle exercise. Am J Physiol Regul Integr Comp Physiol 
301: R534-541, 2011. 
46.  Korhonen, MT, Mero, AA, AléN, M, Sipilä, S, HäKkinen, K, Liikavainio, T, et al. 
Biomechanical and Skeletal Muscle Determinants of Maximum Running Speed with 
Aging: Med Sci Sports Exerc 41: 844–856, 2009. 
47.  Kwatny, E, Thomas, DH, and Kwatny, HG. An Application of Signal Processing 
Techniques to the Study of Myoelectric Signals. IEEE Trans Biomed Eng BME-17: 
303–313, 1970. 
48.  Lauretani, F, Russo, CR, Bandinelli, S, Bartali, B, Cavazzini, C, Di Iorio, A, et al. Age-
associated changes in skeletal muscles and their effect on mobility: an operational 
diagnosis of sarcopenia. J Appl Physiol 95: 1851–1860, 2003. 
49.  Malagoni, AM, Felisatti, M, Lamberti, N, Basaglia, N, Manfredini, R, Salvi, F, et al. 
Muscle oxygen consumption by NIRS and mobility in multiple sclerosis patients. 
BMC Neurol 13: 52, 2013. 
50.  Mancini, DM, Bolinger, L, Li, H, Kendrick, K, Chance, B, and Wilson, JR. Validation of 
near-infrared spectroscopy in humans. J Appl Physiol Bethesda Md 1985 77: 2740–
2747, 1994. 
51.  Martin, JS, Mumford, PW, Haun, CT, Luera, MJ, Muddle, TWD, Colquhoun, RJ, et al. 
Effects of a pre-workout supplement on hyperemia following leg extension 
resistance exercise to failure with different resistance loads. J Int Soc Sports Nutr 
14, 2017.Available from: http://jissn.biomedcentral.com/articles/10.1186/s12970-
017-0195-6 
52.  Martin, PG and Rattey, J. Central fatigue explains sex differences in muscle fatigue 
and contralateral cross-over effects of maximal contractions. Pflugers Arch 454: 
957–969, 2007. 
53.  McCall, DO, McGartland, CP, McKinley, MC, Patterson, CC, Sharpe, P, McCance, DR, 
et al. Dietary intake of fruits and vegetables improves microvascular function in 
hypertensive subjects in a dose-dependent manner. Circulation 119: 2153–2160, 
2009. 
54.  Newman, AB, Kupelian, V, Visser, M, Simonsick, E, Goodpaster, B, Nevitt, M, et al. 
Sarcopenia: alternative definitions and associations with lower extremity function. 
J Am Geriatr Soc 51: 1602–1609, 2003. 
55.  Niemeijer, VM, Spee, RF, Jansen, JP, Buskermolen, ABC, Dijk, T van, Wijn, PFF, et al. 
Test–retest reliability of skeletal muscle oxygenation measurements during 
 71  
submaximal cycling exercise in patients with chronic heart failure. Clin Physiol 
Funct Imaging 37: 68–78, 2017. 
56.  Nilwik, R, Snijders, T, Leenders, M, Groen, BBL, van Kranenburg, J, Verdijk, LB, et al. 
The decline in skeletal muscle mass with aging is mainly attributed to a reduction in 
type II muscle fiber size. Exp Gerontol 48: 492–498, 2013. 
57.  Ohara, M, Kohara, K, Tabara, Y, Ochi, M, Nagai, T, Igase, M, et al. Sarcopenic 
obesity and arterial stiffness, pressure wave reflection and central pulse pressure: 
The J-SHIPP study. Int J Cardiol 174: 214–217, 2014. 
58.  Okamoto, T, Kanazawa, H, Hirata, K, and Yoshikawa, J. Evaluation of oxygen uptake 
kinetics and oxygen kinetics of peripheral skeletal muscle during recovery from 
exercise in patients with chronic obstructive pulmonary disease. Clin Physiol Funct 
Imaging 23: 257–262, 2003. 
59.  Orizio, C, Gobbo, M, Diemont, B, Esposito, F, and Veicsteinas, A. The surface 
mechanomyogram as a tool to describe the influence of fatigue on biceps brachii 
motor unit activation strategy. Historical basis and novel evidence. Eur J Appl 
Physiol 90: 326–336, 2003. 
60.  Orizio, C, Perini, R, and Veicsteinas, A. Muscular sound and force relationship 
during isometric contraction in man. Eur J Appl Physiol 58: 528–533, 1989. 
61.  Paddon-Jones, D, Sheffield-Moore, M, Katsanos, CS, Zhang, X-J, and Wolfe, RR. 
Differential stimulation of muscle protein synthesis in elderly humans following 
isocaloric ingestion of amino acids or whey protein. Exp Gerontol 41: 215–219, 
2006. 
62.  Rasmussen, BB, Fujita, S, Wolfe, RR, Mittendorfer, B, Roy, M, Rowe, VL, et al. 
Insulin resistance of muscle protein metabolism in aging. FASEB J Off Publ Fed Am 
Soc Exp Biol 20: 768–769, 2006. 
63.  Reynolds, JM, Gordon, TJ, and Robergs, RA. Prediction of one repetition maximum 
strength from multiple repetition maximum testing and anthropometry. J Strength 
Cond Res 20: 584–592, 2006. 
64.  Rozand, V, Senefeld, JW, Hassanlouei, H, and Hunter, SK. Voluntary activation and 
variability during maximal dynamic contractions with aging. Eur J Appl Physiol 117: 
2493–2507, 2017. 
65.  Scholkmann, F, Kleiser, S, Metz, AJ, Zimmermann, R, Mata Pavia, J, Wolf, U, et al. A 
review on continuous wave functional near-infrared spectroscopy and imaging 
instrumentation and methodology. NeuroImage 85: 6–27, 2014. 
 72  
66.  Senefeld, J, Pereira, HM, Elliott, N, Yoon, T, and Hunter, SK. Sex Differences in 
Mechanisms of Recovery after Isometric and Dynamic Fatiguing Tasks. Med Sci 
Sports Exerc 50: 1070–1083, 2018. 
67.  Shah, AP, Ichiuji, AM, Han, JK, Traina, M, El-Bialy, A, Meymandi, SK, et al. 
Cardiovascular and endothelial effects of fish oil supplementation in healthy 
volunteers. J Cardiovasc Pharmacol Ther 12: 213–219, 2007. 
68.  Smith, GI, Atherton, P, Reeds, DN, Mohammed, BS, Rankin, D, Rennie, MJ, et al. 
Dietary omega-3 fatty acid supplementation increases the rate of muscle protein 
synthesis in older adults: a randomized controlled trial. Am J Clin Nutr 93: 402–412, 
2011. 
69.  Soares, RN and Murias, JM. Near-infrared spectroscopy assessment of 
microvasculature detects difference in lower limb vascular responsiveness in obese 
compared to lean individuals. Microvasc Res 118: 31–35, 2018. 
70.  Symons, TB, Sheffield-Moore, M, Wolfe, RR, and Paddon-Jones, D. A moderate 
serving of high-quality protein maximally stimulates skeletal muscle protein 
synthesis in young and elderly subjects. J Am Diet Assoc 109: 1582–1586, 2009. 
71.  Timmerman, KL, Dhanani, S, Glynn, EL, Fry, CS, Drummond, MJ, Jennings, K, et al. A 
moderate acute increase in physical activity enhances nutritive flow and the 
muscle protein anabolic response to mixed nutrient intake in older adults123. Am J 
Clin Nutr 95: 1403–1412, 2012. 
72.  Timmerman, KL and Volpi, E. Endothelial function and the regulation of muscle 
protein anabolism in older adults. Nutr Metab Cardiovasc Dis NMCD 23 Suppl 1: 
S44-50, 2013. 
73.  United Nations. World Population on Ageing 2015.  
74.  Vincent, MA, Montagnani, M, and Quon, MJ. Molecular and physiologic actions of 
insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 
3: 279–288, 2003. 
75.  Visser, M. Towards a definition of sarcopenia--results from epidemiologic studies. J 
Nutr Health Aging 13: 713–716, 2009. 
76.  Volpi, E, Mittendorfer, B, Rasmussen, BB, BB, and Wolfe, RR. The Response of 
Muscle Protein Anabolism to Combined Hyperaminoacidemia and Glucose-Induced 
Hyperinsulinemia Is Impaired in the Elderly. J Clin Endocrinol Metab 85: 4481–4490, 
2000. 
 73  
77.  Wüst, RCI, Morse, CI, de Haan, A, Jones, DA, and Degens, H. Sex differences in 
contractile properties and fatigue resistance of human skeletal muscle. Exp Physiol 
93: 843–850, 2008. 
78.  Spectral analysis of muscular sound at low and high contraction level. Int J Biomed 
Comput 23: 161–175, 1988. 
 
 74  
APPENDIX A
 
 
 
 
 
 
 
 
Department of Nutrition and Health Sciences 
211 Ruth Leverton Hall 
University of Nebraska-Lincoln 
Lincoln, NE 68583-0806 
 
IRB #: 18543 
 
Formal Study Title: A pilot study to explore muscle energy metabolism and metabolic 
flexibility in older men and women  
 
Authorized Study Personnel 
 
Principal Investigator:  Joel T. Cramer, Ph.D.  Phone: (402) 472 - 7533 
Study Coordinator:   Brianna D. McKay  Phone: (308) 380 - 7861 
Study Physician:    Heather Eberspacher, MD Phone: (402) 472 - 7480 
Additional Personnel: Zachary Gillen, M.S.  Phone: (402) 472 - 7738 
    Marni Shoemaker, M.S. Phone: (402) 472 - 7738 
Key Information:  
If you agree to participate in this study, the project will involve: 
• Males and females 65 years and older   
• Procedures will include: 
o questionnaires to assess your health status and eligibility 
o body composition assessments including dual-energy x-ray absorptiometry (DXA) 
and ultrasonography 
o one occlusion test using a blood pressure cuff on your thigh for about 5 minutes  
o ten venous blood draws while you rest for 3 hours   
o exercise tests (grip strength, walking speed, balance and chair stand tests, 
walking on a treadmill, and leg extension exercises)  
o surface electromyography and near-infrared spectroscopy 
• Two visits to our laboratory are required  
• These visits will take approximately 9 hours total (Visit 1: 2 hours, Visit 2: 7 hours) 
• The risks of DXA include being exposed to small amounts of radiation that is no greater 
than the amount of natural background radiation received in two days 
• The risks of the occlusion test include leg discomfort while the blood pressure cuff is 
inflated  
• The risk of surface electromyography and near-infrared spectroscopy include mild 
discomfort to local skin areas due to light shaving and cleansing with alcohol wipes 
• The risks of exercise tests include cramping, fatiguing, sweating, or becoming short of 
breath. You may also experience soreness in the days immediately following these tests.  
• The risks of the venous blood samples include potential pain, bruising, or bleeding.  
• You will be paid up to $100 for your participation ($25 for screening, $25 for 
completing Visit 1, $50 for completing Visit 2) 
• You will be provided a copy of this consent form 
• Your participation is voluntary, and you may decide not to participate at any time 
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Invitation 
 
You are invited to take part in this research study. The information in this form is meant to help 
you decide whether or not to participate. If you have any questions, please ask.  
 
Why are you being asked to be in this research study?   
 
You are being asked to be in this study because you are a healthy adult age 65 or older. 
 
What is the reason for doing this research study? 
 
As we age, we tend to lose muscle mass which can lead to a decrease in strength and function. 
Maintaining muscle mass is important for healthy aging. This research is designed to explore 
how your muscles use energy during rest, after eating a meal, and during exercises.  
 
This study is being done at the University of Nebraska-Lincoln (UNL). A total of about 20 
people will participate in this study 
 
What will be done during this research study?  
 
You will be asked to complete 2 study visits, a Screening Visit and a Test Visit, between 4 – 10 
days. The following will be completed during the Screening Visit: 
 
Questionnaires: We will ask you to complete 2 questionnaires. The first questionnaire will ask 
for contact information, demographic information, and a few health history questions to 
determine your eligibility for this study. The second questionnaire will ask about your health 
history to determine if you are able to exercise safely. 
 
Height, Weight, and Waist Circumference: We will ask you to step on a scale to obtain your 
body weight and height, we will use these measurements to calculate your body mass index 
(BMI). We will also use a tape to measure your waist circumference. This procedure will take 
approximately 5 minutes.  
 
Strength and Performance Tests: We will ask you to squeeze a handle as hard as you can to 
obtain your grip strength. We will ask you to complete a series of balance tests with your 1) feet 
side-by-side, 2) heel of one foot against the big toe of the other foot, and 3) feet aligned heel to 
toe. We will also ask you to walk at your normal walking speed on a 4-meter track. Finally, we 
will ask you to complete a chair stand test where we will ask you to raise from the chair 5 times 
with your hands placed across your chest. We will time you as you complete all balance, 
walking, and chair stand tests.  
 
The above items will allow us to determine if you are eligible. If you are eligible for the study, 
you will then complete the following during the screening visit: 
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Dual X-ray Absorptiometry (DXA): We will measure your body composition (how much fat and 
muscle your body is made of) with a dual energy x-ray absorptiometry (DXA) scanner at the first 
visit. You will be asked to remove jewelry, body piercings, clothing with zippers or metal 
buttons, or any clothing containing metal and to put on unrestrictive clothing (provided in the 
laboratory or brought by you) for the scan. You will lie still on a padded table and breathe 
normally for the duration of the scan which is approximately 5 minutes for a whole-body scan. 
 
Ultrasonography: We will also measure composition of your right thigh with a non-invasive 
ultrasound device. Using the ultrasound device, we will take a cross-sectional picture across your 
thigh to measure the cross-sectional area of your quadriceps muscle. We will also take a few 
ultrasound pictures of your thigh at the site of the sensors (see below: Surface Electromyography 
and Near-Infrared Spectroscopy), to measure muscle thickness and adipose tissue thickness.  
 
Post-occlusion Reactive Hyperemia Test: We will place a standard blood pressure cuff around 
the upper portion of your right thigh and inflate the cuff to at least 200mmHg and no higher than 
280mmHg. This is very similar to when you have blood pressure taken on your arm. However, 
we will keep the cuff inflated for at least 5 minutes to maintain arterial occlusion. We will then 
release the blood pressure cuff and ask you to remain laying down with your legs relaxed for 
approximately 10 minutes. During this test, we will have a small device placed on your right leg 
that will monitor oxygenation in your thigh muscles (see Near-Infrared Spectroscopy below).   
 
VO2max Estimation and Leg Extension Strength: We will calculate your maximal aerobic 
capacity (VO2max) using an equation that considers your age, sex, physical activity status, and 
waist circumference. This will tell us how fast we will ask you to walk on the treadmill at your 
second visit. We will also ask you to complete a 5-repetition maximum leg extension test. We 
want to see how much weight you can successfully lift 5 times in a row. This will allow us to 
estimate the maximum amount of weight you would be able to lift one time. This will help us 
determine how much weight we will ask you to lift on your second visit.  
 
If you meet our eligibility criteria, we will also schedule you for the Test Visit. The following 
will be completed leading up to and during the Test Visit: 
 
Food Record Forms and Test Visit Instructions: At the end of your Screening Visit, we will 
provide you a food record form that we will ask you to bring back to the Test Visit. We will ask 
you to record everything you eat and drink for the 3 days preceding your scheduled Test Visit. 
We will also provide instructions for your Test Visit. We will ask you to 1) consume a minimum 
of 150 grams of carbohydrates per day for the 3 days preceding your Test Visit 2) not consume 
alcohol or participate in strenuous exercise the day before your Test Visit 3) fast (no food or 
drink except medications and water) for 8 – 16 hours the night before your Test Visit. Finally, 
we will ask you to wear appropriate clothes and shoes to the test visit so that you can exercise 
safely and comfortably. We will ask you if there were any changes to your health since your 
Screening Visit and we will verify that you adhered to the pre-Test Visit procedures.  
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Blood Draws and Meal Tolerance Tests: We will collect ten 12 mL blood samples (less than 1 
Tbsp. each) from a vein in your forearm during the Test Visit (maximum of 120 mL total).  
The blood draws will be done by a trained phlebotomist who will leave the catheter in your arm 
so we only poke you once. We will ask you to rest in our laboratory for 30 minutes after you 
arrive after which we will complete a fasting blood draw. We will then ask you to eat a meal (1/2 
English muffin with 1 Tbsp. peanut butter and 20 oz. Gatorade) within 15 minutes, and then 
continue resting for up to three hours. During this time, we will collect blood samples every 15 
minutes for the first 90 minutes, and then every 30 minutes up to 180 minutes. During the entire 
resting period, we will ask you to wear a mask that measures how much oxygen you inhale and 
carbon dioxide you exhale. You will also be allowed to watch TV, play games on your phone or 
electronic tablet or read, and have access to toilets. Your blood samples will be analyzed to 
determine serum concentrations of glucose, c-peptide, insulin, amino acids, free-fatty acids, 
gastric inhibitory polypeptide (GIP), and glucagon-like peptide-1 (GLP-1). Additionally, your 
blood samples will be archived for subsequent analysis of unique proteins and other metabolites 
that are intended to help identify additional biomarkers related muscle function. These 
biomarkers may include markers of inflammation e.g., c-reactive protein, interleukin 6,  IGF-1, 
TNF-alpha, and/or muscle tissue injury e.g., 3-methylhistidine. No genetic analysis or disease 
risk assessments will be performed. Your blood samples will be stored in a freezer in a locked 
room in Ruth Leverton Hall with limited access. Only the investigators of this study will have 
access to these samples. All samples will be managed and maintained by Dr. Joel Cramer and 
with the help of his graduate students. When the samples are analyzed at a later date, the results 
will be shared with Abbott Nutrition. By signing this document, you agree to allow your 
biospecimen stored for future analysis and therefore cannot withdraw your blood sample at any 
time.   
Lunch Break: We will give you a 30-minute lunch break where we will provide you a standard 
meal (1 slice of white bread, 1 oz. American Cheese, and 20 oz. Gatorade).  
  
Aerobic and Anaerobic Exercise Tests: We will ask you to walk on a treadmill for 15 minutes at 
low-moderate intensity so we can assess your aerobic metabolism. We will also ask you to 
complete submaximal leg extension exercises until you are unable to complete a repetition 
throughout your full range of motion to assess your anaerobic metabolism. During these two 
tests, we will ask you to wear a mask that measures how much oxygen you inhale and carbon 
dioxide you exhale. During the leg extension test we will also attach sensors to your thigh 
muscles.  
 
Surface Electromyography: During the leg extension tests at the screening visit and test visit, we 
will put non-invasive sensors on your right thigh to measure the activity of your muscle during 
the exercise. We will need to prep your skin before applying the sensors which will consist of 
light shaving and cleansing with alcohol wipes.  
 
Near-Infrared Spectroscopy: We will place a small non-invasive device on your right thigh 
during the post-occlusion reactive hyperemia test and all exercise tests. This device measures 
oxygenation in your muscle. Before securing this device to your thigh with CobanTM wrap, we 
will need to prepare your skin by light shaving and cleansing with alcohol wipes.   
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How will my data be used? 
 
Your data will be sent to researchers outside of the University of Nebraska-Lincoln for the  
purpose of sharing results with the sponsoring company. The data that are sent to these 
researchers will not contain identifiable information, only the participant ID that is linked to your 
personal information. No personal information will be sent to Abbott Nutrition, only coded data 
will be sent.  
 
Your blood samples will not be used for commercial profit and therefore, you will not share in 
any commercial profit from the use of your blood samples.  
 
Your blood samples that are collected for this research study will not include whole genomic, 
germline, somatic, and/or exome sequencing. This means that the researchers have no plans to 
look at or try to “read,” the genetic information from your sample.   
Will I be notified if my blood samples or DXA scan result in an unexpected finding? 
 
When blood samples and DXA results are collected and analyzed, there is the chance of finding 
something unexpected. There may be benefits to learning such results (such as early detection 
and treatment of a medical condition), but there are risks as well (such as feeling worried about a 
finding for which no treatment is required or appropriate). 
 
The results from the blood samples we collect in this research study are not the same quality as 
what you would receive as part of your health care. The blood sample results will not be 
reviewed by a physician who normally reads such results. Due to this, you will not be informed 
of any unexpected findings. The results of your blood samples will not be placed in your medical 
record with your primary care physician or otherwise. If you believe you are having symptoms 
that may require care, you should contact your primary care physician. 
 
In this study, you will be informed of any unexpected findings of possible clinical significance 
that may be discovered during review of results from your DXA scan. The results of your DXA 
scan will not be placed in your medical record with your primary care physician or otherwise.  
 
The results from the DXA scan we collect in this research study are the same quality as what you 
would receive as part of your health care. The results will be reviewed by a physician who 
normally reads such results and they will inform us if there are any unexpected findings and we 
will provide you with this information so that you may discuss it with your primary care 
physician. However, if you believe you are having symptoms that may require care prior to 
receiving any information from this study, you should contact your primary care physician. If 
you would rather not receive incidental findings, please indicate so at the end of this form. 
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What are the possible risks of being in this research study?  
 
This research presents a slight risk of loss of confidentiality since your data will be able to be 
identified and shared with researchers from outside UNL. However, only coded data will be 
shared with researchers from outside UNL.  
 
There is a possibility that you will feel hungry and uncomfortable during the fasting the night 
before each visit, and it may be inconvenient for you to not eat anything.  
 
The risks associated with the exercise tests include cramping, fatiguing, sweating, or becoming 
short of breath. You may also experience soreness in the days immediately following the tests. 
However, this soreness is normal and is naturally alleviated by the body. Stretching exercises 
will be demonstrated for you to help relived cramping, if necessary. Additionally, you will be 
asked repeatedly during the tests how you feel in relation to your ability to continue the test. 
Throughout all tests you will be monitored by study personnel trained in Cardiopulmonary 
Resuscitation (CPR) and use of an Automated External Defibrillator (AED). 
 
The risks associated with blood draw include discomfort at the site of the blood draw, feeling 
dizzy and nauseated, and bruises and blot spots under the skin. Clotting of the blood, blocking of 
arteries, and infections are very rare but are also potential risks. These risks will be reduced or  
eliminated by having only a trained phlebotomist draw blood. Additionally, a trained assistant 
will closely monitor you while you lay down to have your blood collected. Blood will be drawn 
in the laboratory in a sterile (clean) environment.  
 
The risks associated with the post-occlusion reactive hyperemia test include discomfort while the 
blood pressure cuff is inflated on your thigh. You will be asked repeatedly during this test how 
you feel in relation to continue the test.   
 
There are no known risks of surface electromyography or near-infrared spectroscopy. However, 
prepping the skin prior to placement of the sensors includes light shaving and cleaning with 
alcohol wipes. This may cause mild discomfort to the local skin areas. 
 
The amount of radiation exposure received as a result of a whole-body DXA scan is 5 µSv per 
scan (µSv is an abbreviation for micro-Sievert which is a measure of radiation dose). The 
average person living in the United States receives approximately 3000 µSv of radiation dose 
each year from natural sources. The amount of radiation received from a single whole-body 
DXA scan is less than the amount of natural background radiation received in two days, or, in 
other terms, less than 5 % of the radiation received from a standard medical chest X-ray. This 
level of radiation dose is well below known minimum amounts that would result in a direct 
harmful effect (for example, skin redness or rash). However, a possible indirect effect to 
radiation exposure is an additional risk of cancer. The normal risk of developing cancer in the 
general public is approximately 40 %. Based on the most current scientific understanding, the 
additional cancer risk from this procedure is less than 0.001 %. For these reasons, it is thought 
that the risks associated with radiation exposure from this study will be very small. 
__________  
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It is possible that other rare side effects could occur which are not described in this consent form. 
It is also possible that you could have a side effect that has not occurred before.  
 
What are the possible benefits to you?  
 
You are not expected to get any benefit from being in this study. 
 
What are the possible benefits to other people? 
 
This information will progress our understanding of metabolism in older adults, thus the 
knowledge gained from this study may benefit older adults in the future. 
 
What are the alternatives to being in this research study?  
 
Instead of being in this research study you can choose not to participate. 
 
What will being in this research study cost you?  
 
Cost for travel and transport to our laboratory on UNL East Campus will be your responsibility. 
We will provide temporary visitor parking passes for you to park in East Campus parking lots for 
the duration of your Screening Visit and Test Visit.     
 
Will you be compensated for being in this research study?  
 
You will be paid in two separate payments after each visit. You will receive $25.00 cash for the 
screening visit. If you are eligible for the study, you will receive an additional $25.00 cash for 
finishing the testing during the screening visit. If you complete the test visit, you will receive 
$50.00 cash. Therefore, if you complete both visits you will receive a total of $100.00 cash. We 
will ask you to sign a receipt upon receiving your payment after each visit. This signed receipt 
will be securely stored for a minimum of 7 years.  
 
Who is paying for this research? 
 
The sponsor of the research is Abbott Nutrition. The University of Nebraska-Lincoln receives 
money from the sponsor to conduct this study. 
 
What should you do if you have a problem during this research study? 
 
Your welfare is the major concern of every member of the research team. If you have a problem 
or experience harm as a direct result of being in this study, you should immediately contact one 
of the people listed at the beginning of this consent form. If needed, seek immediate emergency 
care for this problem. Please note, it is the policy of UNL not to pay for any required care. 
Agreeing to this does not mean you have given up any of your legal rights. 
 
 
__________  
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In the unlikely event that you should suffer an injury as a direct consequence of the research 
procedures described above, Abbott agrees to pay reasonable medical expenses necessary to treat 
the injury, provided that you follow the directions of the investigator and to the extent that you 
are not otherwise reimbursed by medical insurance. Emergency care is available at local 
community health providers. In the case that you seek medical treatment following an injury, you 
will be asked to sign an Authorization to release your medical records to the IRB and applicable 
associates for review. The study physician, Dr. Heather Eberspacher, will review any adverse 
events that might occur. If the adverse event is considered serious, Dr. Eberspacher will need to 
have access to your medical records for review. 
 
How will information about you be protected?  
 
Reasonable steps will be taken to protect your privacy and the confidentiality of your study data. 
The data will be stored in a locked cabinet in the investigator’s office and will only be seen by 
the research team during the study and will be stored for a minimum of 15 years after the study is 
complete. Your data will receive an identifying number and only the investigators will be able to 
identify you from your data. Furthermore, when your data is sent to Abbott Nutrition, only the 
identifying number that was assigned to you for this study will be used for identification. 
The data will also be stored electronically through a secure server and will only be seen by the 
research team during the study and for a minimum of 15 years after the study is complete. 
 
The only persons who will have access to your research records are the study personnel, the 
Institutional Review Board (IRB), and any other person, agency, or sponsor as required by law. 
Information from this study may be published in scientific journals or presented at scientific 
meetings but the data will be reported as group or summarized data and your identity will be kept 
strictly confidential. 
 
What are your rights as a research subject?  
 
You may ask any questions concerning this research and have those questions answered before 
agreeing to participate in or during the study.  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This website will not include information that can identify you. At most, the 
website will include a summary of the results. You can search this website at any time.  
 
For study related questions, please contact the investigator(s) listed at the beginning of this form. 
 
For questions concerning your rights or complaints about the research contact the Institutional 
Review Board (IRB):  
 
• Phone: 1 (402) 472 - 6965 
• Email: irb@unl.edu 
 
 
__________  
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What will happen if you decide not to be in this research study or decide to stop 
participating once you start?  
 
You can decide not to be in this research study, or you can stop being in this research study 
(“withdraw’) at any time before, during, or after the research begins for any reason. Deciding not  
 
to be in this research study or deciding to withdraw will not affect your relationship with the 
investigator or with the University of Nebraska-Lincoln. 
 
You will not lose any benefits to which you are entitled. 
 
If the research team gets any new information during this research study that may affect whether 
you would want to continue being in the study you will be informed promptly.  
 
The researchers may also make the decision to take you out of the study, even if you want to 
continue, if: 
 
• Your health changes and the study is no longer in your best interest. 
• You do not follow the study rules or no longer meet the requirements to be in the study. 
• The study is stopped by the sponsor, IRB, or researchers.  
 
Documentation of informed consent 
 
You are voluntarily making a decision whether or not to be in this research study. Signing this 
form means that (1) you have read and understood this consent form, (2) you have had the 
consent form explained to you, (3) you have had your questions answered and (4) you have 
agreed to participate in the research study. You will be given a copy of this consent form to keep.  
 
Participant Feedback Survey 
 
The University of Nebraska-Lincoln wants to know about your research experience.  This 14-
question, multiple-choice survey is anonymous. This survey should be completed after your 
participation in this research. Please complete this optional online survey at: 
http://bit.ly/UNLresearchfeedback. 
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Please indicate if you would or would not like to receive unexpected findings regarding 
your DXA scan. The answer to this question will not affect your participation in this study.  
o I would like to receive unexpected findings 
o I would NOT like to receive unexpected findings 
 
Participant Name:  
 
 ______________________________________ 
          (Name of Participant:  Please print) 
 
 
Participant Signature: 
 
 ______________________________________   _______________ 
         Signature of Research Participant             Date 
 
Investigator certification: 
 
 
 
 ______________________________________   _______________ 
         Signature of Person Obtaining Consent             Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please initial to indicate that you have read and understand that you cannot withdraw your blood 
specimens after the project ends because your blood specimens will be de-identified.  
 
__________  
Initial 
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_________________________________________  ____________________________________________ 
AHA/ACSM Health/Fitness Facility Preparticipation Screening Questionnaire 
Assess your health needs by marking all true statements.  
History
If you marked any of the statements in this section, You have had:  
consult your physician or other appropriate healthcare ___ A heart attack provider before engaging in exercise. You may need 
___ Heart surgery to use a facility with a medically qualified staff. 
___ Cardiac catheterization  
___ Coronary angioplasty (PTCA)  
___ Pacemaker/implantable cardiac defibrillator/rhythm disturbance  
___ Heart valve disease
___ Heart failure 
___ Heart transplantation  
___ Congenital heart disease 
Symptoms
___ You experience chest discomfort with exertion. 
___ You experience unreasonable breathlessness.
___ You experience dizziness, fainting, blackouts. 
___ You take heart medications.
Cardiovascular risk factors 
___ You are a man older than 45 years. 
___ You are a woman older than 55 years, you  
Other health issues
          ___ You have diabetes 
___ You have or asthma other lung disease. 
      ___ You have burning or cramping in your lower legs 
when walking short distances. 
           ___ You have musculoskeletal problems that limit your 
physical activity.
___ You have concerns about the safety of exercise.  
___ You take prescription medication(s).  
___ You are pregnant. 
 have had a hysterectomy, or you are postmenopausal. 
___ You smoke, or quite within the previous 6 mo.   
___ Your BP is greater than 140/90.
___ You don't know your BP.  
___ You take BP medication.  
___ Your blood cholesterol level is >200 mg/dL.   
___ You don't know your cholesterol level.  
If you marked two or more of the statements in this 
section, you should consult your physician or other 
appropriate healthcare provider before engaging in 
exercise. You might benefit by using a facility with a 
professionally qualified exercise staff to guide
your exercise program.
___ You have a close blood relative who had a heart attack before age 55 (father or brother) or age 65 (mother or  
sister).  
___ You are physically inactive (i.e., you get less than 30 min. of physical activity on at least 3 days per week).   
___ You are more than 20 pounds overweight. 
___ None of the above is true. You should be able to exercise safely without consulting 
your physician or other healthcare provider in a self-
guided program or almost any facility that meets your 
exercise program needs. 
Balady et al. (1998). AHA/ACSM Joint Statement: Recommendations for Cardiovascular Screening, Staffing, and Emergency Policies at Health/Fitness 
Facilities. Medicine & Science in Sports & Exercise, 30(6).  (Also in: ACSM’s Guidelines for Exercise Testing and Prescription, 7th Edition, 2005. 
Lippincott Williams and Wilkins http://www.lww.com ) 
www.acsm-msse.org/pt/pt-core/template-journal/msse/media/0698c.htm
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Pre-Participation Demographic/Screening Questionnaire 
 
Contact Information:  
Preferred Phone Number: ____________________  
E-mail Address: ____________________________________________ 
Emergency Contact Name: ____________________________________ 
Emergency Contact Phone: ____________________________________ 
Personal Physician: ____________________ Physician’s Phone: ________________________ 
Demographics: 
Your Birthdate: ____________  Age: ______  Sex:  M   F  
Are you: ( ) Hispanic or Latino      ( ) Not Hispanic or Latino     ( ) Prefer not to answer 
Which of the following best describes you?  
 ( ) American Indian or Alaska Native 
 ( ) Asian 
 ( ) Black or African American 
 ( ) Native Hawaiian or Other Pacific Islander 
 ( ) White 
 ( ) Other, please specify: ______________________ 
 
Are you currently participating in any other research studies?  Yes No 
 
Health Status Questions: 
1. Are you able to walk without assistance?     Yes No  
2. Are you post-menopausal?       Yes No N/A 
3. Are you currently participating in a resistance training program?  Yes No  
4. Have you had a poor appetite with any unexplained weight loss 
over the past 6 months?      Yes No   
5. Do you have a current infection (requiring medication or which 
might be expected to require hospitalization)?   Yes No  
6. Have you had inpatient surgery, or corticosteroid treatment  
(excluding topical creams) in the last 3 months, or antibiotics  
in the last 3 weeks?       Yes No  
7. Do you have any chronic, infectious diseases such as active  
Tuberculosis, Hepatitis A, B, or C or HIV?    Yes No  
 
8. Please check (√) if you previously had or currently have any of the following conditions: 
( ) gastrointestinal disease (i.e., Crohn’s, colitis) 
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( ) gastrointestinal surgeries 
( ) gastroparesis  
( ) active malignancy 
( ) liver disease 
( ) kidney disease 
( ) eating disorder 
( ) severe dementia or delirium 
( ) neurological or psychiatric disorder 
( ) alcoholism 
( ) substance abuse 
 
9. Are you allergic or intolerant to any foods?  Yes No 
 If so, please list: _________________________________________________________ 
________________________________________________________________________ 
10. Please list all medications you are currently taking: ______________________________ 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
11. Please list all vitamins or dietary supplements you are currently taking: _____________   
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
 
______________________________      ____________ 
           Participant Signature                Date 
  
